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Abstract 
Histone deacetylases (HDACs) are epigenetic enzymes that modulate chromatin structure 
through the deacetylation of lysine residues in histones, playing a crucial role in cell viability, 
cell cycle progression and tumorigenesis. Yet the role of individual HDACs in these biological 
processes remains enigmatic. Inappropriate recruitment of HDACs is involved in the 
pathogenesis of several forms of leukemia and several lines of evidence point to a role for 
HDACs in tumor progression, consistent with the anti-proliferative and apoptotic effects of 
HDAC inhibitors (HDACi). In this regard, HDACs are considered promising targets for 
development of new molecules for cancer therapy. To date, some HDACi which have a broad 
antitumor activity and low toxicity towards normal cells, such as Romidepsin (Depsipeptide or 
FK228) and SAHA have been approved by U.S. food and drug administration (FDA) for the 
treatment of cutaneous T-cell lymphoma (CTCL). Moreover, HDACi are undergoing clinical 
trials for the treatment of hematological malignancies as well as for solid tumors. Most of the 
HDACi available at the moment are not isoform specific, being active on more than one 
HDAC. Thus, to design more selective HDACi for cancer therapy it is important to elucidate 
the role of individual HDACs. 
Acute Promyelocytic Leukemia (APL) is the first model disease in which the involvement of 
HDACs has been documented. APL is a subtype of Acute Myeloid Leukemia (AML), a cancer 
of blood and bone marrow, which is characterized by hyperproliferation of immature 
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granulocytes blocked at the promyelocytic stage. It is genetically associated with a 
chromosomal translocation t(15;17)(q22;q21), which encodes the oncogenic fusion protein 
PML-RARα found in more than 90% of APL patients. In murine models of APL that 
recapitulate the human disease, PML-RARα induces a “pre-leukemic” stage with long latency 
and without an overtly dramatic phenotype before full leukemic transformation. In fact, for 
this reason it is assumed that in addition to this oncogenic fusion protein, other genetic hits are 
required for clonal expansion of leukemic blasts. This fusion protein recruits a number of 
chromatin modifier enzymes such as HDACs and DNA methyltransferases (DNMTs) to the 
promoter of retinoic acid (RA) target genes and transcriptionally silence them, leading to the 
myeloid differentiation block. Furthermore, PML-RARα causes the impairment of p53 
pathway by deacetylation and degradation of p53 through the recruitment of HDAC- 
containing complexes. HDACs from class I (HDACs 1, 2 and 3) have been found associated 
with PML-RARα paving the way for the use of HDACi for APL treatment. Recently, a study 
on APL, which has been conducted by Santoro et al., showed that among class I HDACs, 
HDAC1 and to a lesser extent HDAC2 have a dual role in APL development and maintenance. 
In fact, while they behave as oncosuppressors at the early stages, they function as oncogenes 
in established tumor cells. Since inhibition of HDAC1 and HDAC2 in pre-leukemic stage 
leads to the acceleration of the disease in murine models of leukemia, it suggests caution in the 
clinical utility of epidrugs that target any of these two HDAC isoforms. Moreover, it has been 
shown that the expression of HDAC3, which associates with nuclear hormone corepressor and 
silencing mediator of retinoid hormone (NCoR/SMRT) complex, is frequently increased in 
tumors, while Hdac3 downregulation results in reduced proliferation and survival of tumor 
cells.  In view of these observations, in this study we functionally assessed the role of HDAC3 
in the development and maintenance of APL. To achieve our goal, we have dissected the role 
of HDAC3 in two different phases of the disease: pre-leukemic phase and full-established 
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leukemia. The murine model of APL, which we used, is the mCGPR/PR mouse model in which 
PML-RARα is expressed under the control of the cathepsin G promoter. The mice show a very 
long latency (the pre-leukemic phase) associated with high penetrance (more than 90% of the 
mice develop APL).  
We characterized the role of HDAC3 through a functional knock-down approach, assessing its 
impact on cellular differentiation, proliferation and the ability to influence the transplantation 
of HSCs and APL cells. Indeed, Hdac3-KD in vitro reduced the proliferative potential of both 
pre-leukemic and full leukemic cells and boosted their differentiation, suggesting that HDAC3 
plays the role of an oncogene in APL initiation and progression. These results were not 
restricted to APL, because lymphoma driven by c-myc overexpression and leukemia driven by 
MLL-AF9, were both impaired in cell growth upon Hdac3-KD. In vivo, inoculation of Hdac3-
KD pre-leukemic cells into lethally irradiated recipient mice or inoculation of Hdac3-KD APL 
cells into the recipient mice did not result in leukemia development or progression, 
respectively. These results suggest that HDAC3 can be considered as a target for epidrugs in 
the treatment of hematological malignancies. Thus, we assessed this hypothesis with the 
treatment of pre-leukemic and leukemic cells with the HDAC3 selective inhibitor, RGFP966. 
Indeed, inhibition of HDAC3 enzymatic activity with RGFP966, phenocopied Hdac3-KD 
phenotypes in pre-leukemic and leukemic cells confirming the putative oncogenic role of 
HDAC3. 
In conclusion, my PhD project has expanded our comprehension about the role of HDAC3 in 
hematological malignancies and is beginning to unravel alternative views on the targets of 
epidrugs for the treatment of leukemic patients. 
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Introduction 
1. Hematopoiesis: 
Hematopoiesis serves as a paradigm for studying the role of stem cells in differentiation and 
development. Establishment and maintenance of the blood system relies on self-renewal 
ability of hematopoietic stem cells (HSCs), rare cells which reside in specific niches in the 
bone marrow (BM) of adult mammals. A wide variety of cellular morphologies corresponding 
to cells of various blood lineages and stages of differentiation have been found in the BM 
anatomic examination (1). To explain this diversity, A. Maximow in 1909 postulated that 
hematopoiesis is hierarchically organized. In this picture, BM cells derive from a common 
precursor (i.e. HSCs) that sits atop a hierarchy of progenitors that progressively commit to 
several or single lineages. The first evidence for the existence of HSCs came from the study 
conducted by Lorenz and colleagues in 1951, which showed that injection of syngenic spleen 
or BM cells from a donor could reconstitute the hematopoietic system of an irradiated 
recipient (2). HSCs are enriched for a population that are negative for lineage markers (Lin-) 
and positive for Sca.1 and c.Kit (LSK cells). The LSK cells include long-term self-renewing 
subset (LT-HSC), short-term HSC (ST-HSC) and multipotent progenitors (MPPs). The LT-
HSC undergoes an asymmetric cell division and generates another LT-HSC that maintains the 
stem cell pool and a transient self-renewing ST-HSC that self-renews within a limited time 
window (3, 4). Further differentiation of ST-HSC generate MPPs and then oligopotent 
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progenitors, notably common myeloid progenitors (CMPs) and common lymphoid progenitors 
(CLPs), which respectively give rise to different myeloid and lymphoid lineages. Downstream 
of CMPs, there are megakaryotic/erythroid progenitors (MEPs), which differentiate to 
megakarycytes/platelets or erythrocytes and myelo-monocytic progenitors, and 
granulocyte/macrophage progenitors (GMPs) that produce macrophages, monocytes and 
granulocytes. On the other hand, CLPs can differentiate into B and T lymphocytes or natural 
killer cells (NK) (5-7) (Figure 1). 
 
 
Figure 1. Schematic representation of hematopoietic hierarchy. At the apex of the hierarchy LT-
HSC, long-term repopulating HSC; ST-HSC, short-term repopulating HSC; CMP, common myeloid 
progenitor; CLP, common lymphoid progenitor; MEP, megakaryocyte/erythroid progenitor; GMP, 
Granulocyte/macrophage progenitor. Lin- Sca+ c.Kit+ cells refer to encircled pluripotent population (i.e. 
LT-HSC, ST-HSC and MPP). Adapted from Larsson and Karlsson ,Oncogene, 2005 (8). 
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2. Deregulation of hematopoiesis: 
Hematopoiesis as a developmental program is orchestrated by changes in the pattern of gene 
expression, which is directed by transcription factors (TFs). When the action of TFs is 
deregulated due to chromosomal aberrations (chromosomal translocations, deletions and 
inversions), gene mutations or deregulation of epigenetic modifiers, hematopoiesis fails 
leading to the differentiation block and abnormal cell proliferation. Eventually, these events 
cause development of leukemia (9). The most common acute leukemia affecting adults is 
acute myeloid leukemia (AML), which is known as a transcriptional disease. The main 
characteristic of AML is a severe block in myeloid differentiation characterized by rapid 
clonal proliferation of immature myeloid cells in the BM, that infiltrate other organs of the 
body (10-13). AML is a heterogeneous disease for which the standard treatment with cytotoxic 
chemotherapy has remained largely unchanged for over four decades, with unfavorable 
clinical results (14-16). Recently, the advent of massive parallel sequencing has revealed that 
>70% of AML cases have mutations in DNA methylation-related genes or mutations in 
histone modifiers. These data indicate that epigenetic alterations are key players in the 
development of most, if not all AMLs, and point to the concept that epigenetic alterations are 
as relevant as genetic mutations in leukemia development, paving the way for the use of drugs 
targeting epigenetic modifier enzymes (17). 
 
 
3. Epigenetics: 
3.1 Concept of epigenetics: 
The basic functional and structural unit of all living organisms except viruses is known as the 
cell, which is often called “the building block of life”. Multi-cellular organisms arise from a 
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single cell and generate multi-cellular organisms through the cell division. There are hundred 
types of cells in human body, and their functions and morphologies vary from one to the other. 
Based on the human genome project approximately around 20,000 to 25,000 genes exist in the 
human genome but not all of these genes are expressed in each cell. In more details, while the 
majority of cells in multi-cellular organisms have an identical genotype, through development 
they will generate a diversity of cells with different functions and stable profile of gene 
expression. Regulation of gene expression patterns, which is involved in cell fate 
determination, is processed by epigenetic changes. Therefore, cellular differentiation can be 
considered as an epigenetic phenomenon, which results from the interplay between genes and 
environment, what Conrad Waddington defined as “ epigenetic landscape” (Figure 2) (18). 
Historically the term epigenetics stands for: “Any meiotically or mitotically heritable changes 
on gene expression without changes in DNA sequence” (19, 20). This definition nowadays is a 
bit controversial, because the word epigenetics is also used for describing any dynamic 
alterations that may or may not be heritable, still resulting in gene expression changes (21). 
The altered epigenetic pattern is central to many human diseases; the best-known example so 
far is cancer. Comparison of the genome of tumor cells with normal cells of the same 
individual shows a massive loss of DNA methylation, accompanied by aberrant activity of 
chromatin modifier enzymes and pattern of histone modification, resulting in a distorted 
epigenetic landscape of cancer. To appreciate the mechanisms behind epigenetic regulation, it 
is important to find the core molecular actors, which have key roles in epigenetic alterations. 
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Figure 2. C.H. Waddington’s epigenetic landscape model. Waddington first proposed the concept of 
epigenetic landscape in 1957; this figure represents the process of cellular differentiation and different 
trajectories that the cell (demonstrated by a ball) can undertake toward differentiation. Actually in this 
dynamic visual metaphor, the cell can go through specific paths that lead to different cell fates.  
Adapted from Goldberg et al, Cell, 2007 (18). 
 
3.2 Nucleosome structure and stability: 
When a cell undergoes proliferation, DNA replicates through the cell cycle. In higher 
organisms the nuclear DNA is tightly compacted and wrapped around nuclear proteins (termed 
histones) thereby forming the chromatin, which can be easily housed in the eukaryotic 
nucleus. Chromatin modifications have profound implications in the regulation of key 
biological processes such as DNA repair, replication and transcription. It is becoming clear 
that due to the important role of chromatin modifications in the above mentioned vital cell 
processes, aberrations in chromatin modifier enzymes also known as epigenetic modifiers can 
lead to abnormal cell functions and consequently cause the development of various diseases 
or/and cancer. The repeating building unit of chromatin is the nucleosome, which is composed 
of around 145-147 base pairs (bp) of DNA spooled two rounds around an octamer of histones 
consisting of two copies of H2A, H2B, H3 and H4. H1, known as linker histone, provides 
further structural stability through binding to DNA, which enters and exits from the 
nucleosome.  
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Nucleosomes are connected to each other through a linker DNA or a short DNA segment; 
these linked nucleosomes undergo short-range interactions with neighboring nucleosomes and 
form chromatin fibers. Higher order chromatin structure will be formed by fiber-fiber 
interactions (22) (Figure 3). Based on the state of chromatin condensation, there are two 
major regions: euchromatin and heterochromatin. Euchromatin is known as “relaxed” state or 
open configuration and is more prevalent in cells which are active in the transcription of many 
of their genes; in other word it comprises the most active portion of the genome (23). 
Euchromatin is characterized by high levels of histones acetylation and H3K4, H3K36 and 
H3K79 trimethylation (24). On the other hand, heterochromatin is considered as “closed” 
state, and is correlated with transcriptional repression, gene silencing (20, 22, 25), low levels 
of histones acetylation and high levels of H3K9, H3K27 and H4K29 methylation.  
 
Figure 3. Schematic depiction of nucleosome structure. Adapted from 
www.zoology.ubc.ca/~bio463/lecture_3.htm 
 
3.3 Epigenetic modifications: 
Epigenetic modifications can be grouped into three main categories: DNA methylation, 
nucleosome positioning and histone post-translational modifications (PTMs). 
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3.3.1 DNA methylation: 
The process of adding a methyl group into C5 of cytidine ring of DNA in the context of CpG 
dinucleotides (5mC) is generally associated with heterochromatin formation and 
transcriptional repression. This modification is catalyzed by a family of enzymes known as 
DNA methyltransferases (DNMTs). DNMT1 is required for the maintenance of methylation 
during DNA replication and targets hemi-methylated DNA, while DNMT3A and DNMT3B 
are required for de novo methylation (26). Regulation of gene expression by DNA methylation 
of target gene promoters is important for control of several developmental processes including 
hematopoiesis, X chromosome inactivation (27) and genomic imprinting (28). DNA 
methylation patterns are perturbed in many human cancers and DNA hypermethylation is 
usually observed at genes with tumor suppressor actions (29, 30). 
 
3.3.2 Nucleosome positioning: 
As mentioned previously, condensation of DNA into nucleosomes can affect all stages of 
transcription. It acts as a barrier for transcription initiation by blocking the access of 
transcriptional machinery to their binding sites on DNA, particularly in transcription start sites 
(TSSs), or inhibits the transcription elongation by engaged polymerases; all of these events 
regulate gene expression. Therefore, nucleosome positioning determines the accessibility of 
transcription factors to their target DNA and it is also involved in shaping the methylation 
landscape (31, 32). In addition to transcription regulation, nucleosome positioning directs 
mitotic recombination events. Nucleosome positioning and gene expression are regulated 
through the activity of histone variants. For instance, the genes will be protected against DNA 
methylation by the incorporation of histione variant H2A.Z. Histone variants are the key 
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modulators of nucleosomes’ function. There are some important differences between histone 
variants and core histones. Specially, histone variants are expressed outside of S phase and are 
incorporated into chromatin independently from DNA replication, and furthermore their 
histone tails also differ from core histones (9). In addition to DNA methylation and specific 
histone methylation, nucleosome remodeling and spacing are influenced by the activity of 
chromatin remodeling complexes. These complexes are classified into four families: i) 
SWI/SNF family that is the master regulator of gene expression and modulates alternative 
splicing. ii) ISWI family, which promotes chromatin assembly and represses transcription. iii) 
CHD family that participates in nucluosome sliding and transcription promotion. iv) INO80 
family, which is involved in DNA repair, transcriptional activation and DNA replication (31). 
 
3.3.3 PTM of histone proteins: 
All histones are subjected to post-translational modifications and these modifications serve as 
signaling mechanisms and as binding platforms for the recruitment of other proteins. Several 
post-translational modifications occur in histone tails (N-terminal of histone residues) as well 
as within globular domain of histones, such as acetylation, methylation, phosphorylation, 
ubiquitination, sumoylation  and biotinylation (32). Epigenetic writers and erasers respectively 
govern addition or removal of these PTMs, and then epigenetic readers recognize and bind to 
certain histone modifications. 
 
3.3.3.1 Histone acetylation and deacetylation: 
Acetylation and deacetylation of histones (Figure 4) have emerged as critical modulators of 
chromatin status, respectively act on transcriptionally active and inactive chromatin domains. 
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Histone acetyltransferase enzymes (HATs), known as epigenetic writers, add the acetyl group 
from acetyl-coA to the ε-amino site of lysine residues in histones and non-histone proteins 
neutralize their positive charges, leading to the relaxed chromatin structure and makes it 
accessible for the transcription machinery. Importantly, acetylation of  proteins can affect 
protein stability, protein-protein interaction, protein localization and DNA binding of 
transcription factors (33). HATs are divided into 2 types based on their cellular localization, 
type A; which are localized in the nucleus and type B; which are found in the cytoplasm. 
Furthermore, type A HATs are classified into 3 main families based on their homology and 
acetylation mechanisms: 1) the GNAT family (such as PCAF and Gnc5); 2) CBP/p300 family 
and; 3) MYST family (including Tip60, MOZ, MORF, HMOF and HBO1) (34). ε-N-
acetylation of lysine residues are recognized and read by bromodomain-family proteins. The 
human proteome encodes 61 bromodomains, which are present in 46 diverse nuclear and 
cytoplasmic proteins (35). The antagonist role is imposed by Histone deacetylase enzymes 
(HDACs), which modulate chromatin structure through the deacetylation of lysine residues in 
histones and non-histone proteins, and playing crucial roles in cell viability, cell cycle 
progression and tumorigenesis. However, the role of individual HDACs in these biological 
processes remains enigmatic (36). The balance between the activity of these two types of 
enzymes acts as a key regulator of gene expression and developmental processes (37). 
Initially, it was thought the key substrates for  HDACs were histones, but further  phylogenetic 
studies showed that they evolved earlier than histones and they can also deacetylate non-
histone proteins such as transcription factors, polyamines and metabolic intermediates (33, 
38). Deacetylation of non-histone proteins mainly results in their degradation through 
ubiquitin-proteosome pathway (39). HDACs do not contain DNA binding domains, but they 
can be aberrantly recruited to the promoter of target genes through the association with 
transcription factors, nuclear receptors and oncogenic fusion proteins that result from 
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chromosomal translocations. In recent years, these types of enzymes, particularly HDACs 
arose as key targets in therapeutic arena for reversing aberrant changes associated with 
different types of cancers and non-cancer diseases (40). Inappropriate recruitment of HDACs 
is involved in the pathogenesis of several forms of leukemia (41) and several lines of evidence 
point to a role for HDACs in tumor progression, consistent with the anti-proliferative and 
apoptotic effects of HDAC inhibitors (HDACi) (42). In this regard, HDACs are considered 
promising targets for developing new molecules for cancer therapy (33, 36). For example it 
has been shown PML-RARα which is involved in induction of Acute promyelocytic leukemia 
(APL) recruits HDAC-containing complexes to the promoter of specific target genes and 
consequently represses their expression (43). 
 
 
Figure 4. HAT and HDAC enzymatic activity. Acetylation of histones, catalyzed by histone acetyl-
transferase (HAT) and deacetylation of histones catalyzed by histone deacetylases (HDACs). Modified 
from Kouraklis and Theocharis, Oncology reports, 2006 (44). 
 
4. HDAC superfamily: 
There are 18 HDACs in mammals, which can be classified into 4 classes, based on their 
enzymatic activity and their homology to yeast HDACs: class I (HDAC1, 2, 3 and 8), class IIa 
and IIb (HDAC 4, 5, 6, 7, 9, 10), class III (Sirtuins1 to 7) and class IV (HDAC11) (45) 
(Figure 5). With the exception of class III, which has a Nicotinamide adenine dinucleotide 
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(NAD+)-dependent action, all other classes are zinc (Zn 2+) dependent HDACs, and use the 
zinc ion as the cofactor for the deacetylation activity through a charge-relay-system. Class III 
sirtuins have widely distinct functions and subcellular localization compare to the other 
HDACs and while the roles of sirtuins in cancer are still debatable, their involvement in age 
associated diseases, including Alzheimer’s and Parkinson’s is well characterized (46, 47). The 
activities of HDAC enzymes are vital for cell proliferation, differentiation and normal cell 
development, as demonstrated by the embryonic lethality phenotype observed upon knockout 
(KO) of different Hdacs (e.g. Hdac1, 2, 3 and 4) (42, 46, 48). 
 
4.1 Class I HDACs 
Class I HDACs comprises HDAC1, 2, 3 and 8, which display higher enzymatic activity 
against histones. This class of HDACs is the most abundant and ubiquitously expressed 
HDACs, all contain a nuclear localization signal (NLS) thus predominantly are found in the 
nucleus. They have homology to the yeast HDAC, Rpd3. Based on phylogenetic studies this 
class of HDACs can be sub-divided into 3 classes, Class IA (HDAC1 and 2), Class IB 
(HDAC3) and Class IC (HDAC8) (38). These HDACs do not bind directly to DNA but 
instead are usually the catalytic component of multi-protein complexes. Repressive complexes 
such as Sin3 (Swi independent 3), Mi-2/NuRD (Nucleosome remodeling deacetylase), and 
CoREST (corepressor of repressor element 1 silencing transcription) mainly recruit HDAC1 
and HDAC2 which share 82% identity and are the most similar members of class I, while 
HDAC3 is found in distinct complexes such as NCoR-SMRT (nuclear receptor corepressor- 
silencing mediator of retinoid and thyroid). Till now, no complex that recruits HDAC8 has 
been described, therefore it seems that HDAC8 can carry out its function independent of 
multi-protein complexes. HDAC3 was first identified in 1997 in a study which has been 
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conducted by Wen-ming yang et al. (49). HDAC3 is composed of 428 amino acids with a 
molecular mass of 49 kDa. It shares approximately 53% and 52% identity with HDAC1 and 
HDAC2, respectively (50). 
Generation of mouse models harboring deletions of class I HDACs made it feasible to study 
the biological functions of these HDAC isoforms. Deletion of Hdac1 led to embryonic 
lethality (E10.5), which established a crucial role for HDAC1 in embryogenesis (51).  Hdac1-
null (Hdac1-/-) embryonic stem cells (ESCs), due to the increased expression of cell cycle 
inhibitors p21 and p27, showed proliferative defects (52).  Deletion of Hdac2 did not result in 
embryonic lethality but led to severe cardiac malformations that caused the death of most of 
mice within 24 hours after birth (53). Dovey et al. generated conditional knockout embryonic 
stem (ESCs) in which Hdac1 or Hdac2 genes could be inactivated. Deletion of Hdac1, but not 
Hdac2 in ESCs, caused a significant reduction in the HDAC activity of Sin3A, NuRD, and 
CoREST corepressor complexes accompanied with a 1.6 fold increase in the acetylation of 
H3K56. Proliferation potential of ESCs was unaffected by loss of either Hdac1 or Hdac2. 
However, loss of Hdac1 impaired ESC differentiation (54). Hdac3-KO mice had an 
embryonic lethal phenotype before embryonic day 9.5 (E9.5), which showed a vital role for 
HDAC3 in embryogenesis and normal development (36). Upon removal of Hdac3 in a mouse 
embryonic fibroblast (MEF) model, they underwent apoptosis and showed delay in cell cycle 
progression (55). Furthermore, tissue specific deletion of Hdac3 in the liver was generated by 
using Cre recombinase under the control of albumin promoter (Cre-Alb). Removal of Hdac3 
upon administration of Tamoxifen, led to hypertrophy of liver and disrupted metabolism (56). 
In order to study the role of HDAC3 in hematopoiesis, another mouse model, Hdac3:Vav-Cre 
was generated. These mice showed a remarkable loss of lymphoid cells, stem and progenitor 
cells proliferation, and DNA replication defects (57).There are some evidence which shows 
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that global Hdac8 deletion led to perinatal lethality due to skull instability, revealing an 
essential role for HDAC8 in patterning of the skull (58). 
 
4.1.1 Class I HDAC-containing complexes: 
Sin3: Sin3 was first identified as a global transcription regulator. 11 subunits make up Sin3 
complex and are conserved from yeast to mammals (59). There are two Sin3 homologs in 
mammals; Sin3A and Sin3B. The Sin3A complex is composed of HDAC1 and HDAC2 as 
catalytic components and 9 other subunits as regulatory components including; binding 
proteins, Retinoblastoma associate protein 46 (RbAp46) and RbAp48 (60). Since Sin3/HDAC 
complexes lack DNA-binding activity they must be targeted to the gene promoters through the 
interaction with DNA-binding proteins (61). 
Mi-2/NuRD: Mi-2/NuRD is a multi-subunit protein complex comprising HDAC1/2, ATP-
dependent remodeling enzymes CHD3/4, histone chaperones RbAp46/48, CpG-binding 
proteins MBD2/3, the GATAD2a (p66α) and/or GATAD2b (p66β) and specific DNA-binding 
proteins MTA1/2/3 and Mi-2 (62, 63). 
CoREST: CoREST was originally described as corepressor of REST (RE1-silencing 
transcription factor) found in complex with HDAC1 and HDAC2 and with additional subunits 
including sox-like proteins and the histone demethylase LSD1 (H3K4 demethylase) (64). 
NCoR-SMRT: NCoR-SMRT are essential factors for HDAC3 activity, and both of them have 
a conserved deacetylase-activating domain (DAD) for HDAC3 activation (65). Studies which 
conducted on HDAC3 structure in 2012, showed that N-terminal helix of the DAD undergoes 
conformational changes upon forming complex with HDAC3 resulting in the standing of DAD 
on the surface of HDAC3. Further analysis led to discovery of inositole tetraphosphates 
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molecule (Ins (1, 4, 5, 6) P4 or IP4) as an essential requirement for the interaction between 
DAD of SMRT and N-terminal of HDAC3. All these discoveries on HDAC3 structure and its 
interaction with co-repressor complexes provide novel opportunities for therapeutic 
intervention through HDAC3 targeting (66). In addition to HDAC3, the members of class IIa 
HDACs interact with NCoR-SMRT complex through RD3 domain of NCoR. It has been 
shown that while HDAC3 is catalytically activated after binding to NCoR-SMRT complex, 
class IIa HDACs are not, and NCoR-SMRT actually serves as a bridge between HDAC3 and 
class II HDACs (67). 
 
4.2 Class IIa HDACs 
This class of HDACs is composed of HDAC4, 5, 7 and 9. They have similarity with the yeast 
HDA1 deacetylase. HDAC4 and HDAC5 have an overall similarity of 70%. Interestingly, 
HDAC4, 5 and 7 associates with HDAC3 through the recruitment into the NCoR/SMRT 
complex and disruption of this association leads to the inactivation of the enzymatic activity of 
these three HDACs (67). Class IIa HDACs bind to 14.3.3-chaperon protein following the 
phosphorylation by kinases and then shuttle from nucleus to the cytoplasm. For instance 
studies conducted in muscle cells have shown that upon a pre-differentiation signal HDAC4 is 
phosphorylated by Ca2+/calmodulin-dependent kinase (CaMK) and then is exported to the 
cytoplasm remaining there through the interaction with 14.3.3 protein. After receiving the 
post-differentiation signals, i.e. after fusion of muscle cells, its phosphorylation level is 
reduced leading to the release from the 14.3.3 protein and allowing it to shuttle back to the 
nucleus (65). These HDACs can also recruit class I HDACs through their C-terminal domain 
and among these HDACs, HDAC4, 5 and 7 are able to interact with NcoR/SMRT and Bcl6-
interacting co-repressor (BCoR) (65, 67). In contrast to other HDACs the members of this 
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class are expressed in a tissue-specific manner. For example HDAC4 is highly expressed in 
brain (68, 69), HDAC5 and HDAC9 are enriched in muscles and HDAC7 in endothelial cells 
and thymocytes (37). 
 
4.3 Class IIb HDACs 
HDAC6 and HDAC10 belong to class IIb family. HDAC10 is involved in angiogenesis (70), 
modulation of HSP90 acetylation in cooperation with HDAC6 and regulation of homologous 
recombination in cooperation with HDAC9 (71). Two Rb-binding domains have been found 
on HDAC10, suggesting it may have a role in cell cycle regulation. HDAC6 is the main 
cytoplasmic deacetylase in mammalian cells and structurally different from all other HDACs 
because it contains two deacetylase domains and a C-terminal zinc finger domain: this domain 
acts as a signal for ubiquitination. HDAC6 targets and deacetylates transmembrane proteins 
such as interferon receptor and cytoskeletal proteins including α-tubulin and cortactin (37). 
Reversible acetylation of α-tubulin at Lys40 by HDAC6 has been implicated in regulating 
microtubule stability and function. In vivo, the overexpression of Hdac6 leads to a global 
deacetylation of α-tubulin, whereas downregulation of Hdac6 results in α-tubulin 
hyperacetylation. In vitro, purified HDAC6 potently deacetylates α-tubulin in assembled 
microtubules. Furthermore, overexpression of Hdac6 promotes chemotactic cell movement 
supporting the idea that HDAC6-mediated deacetylation, regulates microtubule-dependent cell 
motility. HDAC6 has also an important role in aggresome formation and directing the 
misfolded proteins to the aggresome. Thus, loss of HDAC6 activity impacts on cell viability in 
response to misfolded proteins (72, 73). 
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4.4 Class III HDACs 
This class is composed of 7 mammalian sirtuins (SIRT1-7); they are NAD+- dependent protein 
deacetylases. Sirtuins have homology to the yeast silencing information regulator 2 (Sir2), 
which has been identified as a transcriptional repressor of mating type loci and telomeres, 
which prolongs survival in yeast. The members of this family have gained attention in recent 
years due to their regulatory role in metabolic diseases, such as obesity and type 2 diabetes 
and in ageing. According to their subcellular localization they can be found in nucleus (SIRT1, 
SIRT6 and SIRT7), in mitochondria (SIRT3, SIRT4 and SIRT5) and cytoplasm (SIRT2) (74).  
Based on phylogenetic analysis, they can be divided into 4 subgroups; class I (SIRT1, SIRT2 
and SIRT3), class II (SIRT4), class III (SIRT5) and class IV (SIRT6 and SIRT7) (75). The 
members of this class have a dual role as oncogenes and oncosuppressors (76, 77). 
 
4.5 Class IV HDACs 
The sole member of this class is HDAC11, which is mainly expressed in the brain, heart 
kidney and muscles. Based on phylogenetic studies, it is mainly related to HDAC3 and 
HDAC8. HDAC11 enzymatic activity which is driven by a catalytic domain on its N-
terminus, can be inhibited by trapoxin (an analogue of TSA) (65). 
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Figure 5. Structure of HDACs superfamily. This figure indicates the structure of different members 
of HDACs superfamily, their subcellular localization, length and their chromosomal location in Homo 
sapiens. Adapted from Bolden et al, Nature reviews. Drug discoveries, 2006 and Kim et al, American 
journal of translational research, 2011 (43, 74, 78). 
 
5. HDACs and hematological malignancies: 
APL is the first and the best-known example of hematological malignancies in which the 
involvement of HDACs has been demonstrated. This leukemia, being the focus of this 
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dissertation, will be discussed in details in sections 9, 10 and 11. Another example of HDAC 
involvement in the molecular mechanism of leukemogenesis is the leukemia subtype M2 
derived from t(8;21) AML1-ETO chromosomal translocation, expresses in 12% of AML 
cases. AML1 is an important protein in hematopoietic development, and ETO is a corepressor. 
In AML1-ETO fusion protein, AML1 moiety retains its ability to bind to DNA and ETO 
moiety confers new docking sites for HDAC-containing complexes. Thus, this fusion protein 
acts as a transcriptional repressor of AML1-regulated genes (79). The differentiation block 
that is mediated by AML1-ETO is partially reversed by HDACi, that supports the involvement 
of HDACs in this type of leukemia (80). Inv(16) which makes up 8% of AML cases, results in 
fusion of the CBFβ transcription factor, a master transcription factor for myeloid 
differentiation and granulocytic maturation, with the smooth muscle myosin heavy chain gene 
MYH11. In this chromosomal aberration the resultant fusion protein recruits the HDAC 
containing complexes and consequently represses AML1-transactivated genes (80, 81). 
Similarly to the hematological malignancies reported above, HDAC6 has been identified as 
the HDAC involved in the pathogenesis of Chronic Myelogenous Leukemia (CML) that is 
driven by t(9;22) (Bcr-Abl). Indeed, HDAC6 deacetylates HSP90, the cellular chaperone 
whose overexpression correlates with poor prognosis in tumor cells. HSP90 binds to a variety 
of client proteins such as Bcr-Abl, Flt3, Erb B2 and c-Raf and prevents their ubiquitination 
and proteosomal degradation. Thus, inhibition of HDAC6 enzymatic activity with inhibitors 
such as Tubacin, leads to hyperacetylation of HSP90 and degradation of Bcr-Abl (82). 
Among distinct forms of hematopoietic malignancies in which HDAC-dependent 
transcriptional repression has been implicated in the pathogenesis of the disease, non-
Hodgkin’s lymphomas, diffuse large B-cell lymphoma (DLBCL) and the Follicular lymphoma 
can be named, in which B-cell lymphoma 6 (BCL-6) is the involved transcriptional repressor 
that is associated with class I and class II HDACs (83). BCL-6 acetylation by HAT p300 
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disrupts its ability to recruit HDACs and transform cells (80). One type of cancer that has 
shown tremendous improvement upon treatment with HDACi is CTCL, a heterogeneous 
group of non-Hodgkin’s lymphoma that is characterized by an initial accumulation of 
malignant, mature T cells in the skin (84). Furthermore, development of T-cell acute 
lymphoblastic leukemia (T-ALL) in which SCL-TAL1 transcription factor is overexpressed, is 
due to the repression of genes involved in thymocytes differentiation and survival through the 
recruitment of HDAC1 containing complexes by the SCL-TAL1 (85). Thus, according to the 
described role of HDACs in different hematological malignancies, HDACi can be considered 
effective compounds for the treatment of these types of diseases. Far away from all the above-
mentioned features, currently the role of individual HDACs in leukemogenesis remains largely 
unexplored with the exception of a few recent studies (86, 87). 
 In addition to aberrant recruitment of HDACs by oncogenic fusion proteins to specific loci in 
hematological malignancies, the altered expression of Hdacs have been demonstrated in non-
hematological malignancies. Increased expression of Hdac1 has been shown in gastric, 
prostate and colon cancer, Hdac2 is overexpressed in colorectal and cervical cancer, Hdac3 is 
overexpressed in colon cancer (88). Moreover, HDAC8 has an important role in the 
pathogenesis of neuroblastoma (79). All these studies highlight the importance and widespread 
therapeutic potential of HDACi and introduce HDACs as potential targets for therapeutic 
intervention. 
 
6. HDAC inhibitors (HDACi): 
The anti-tumor potential of small molecules, which interfere with the activity of HDACs, has 
led to development of a variety of HDACi. Difference in therapeutic potential of HDACi 
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stems from their active concentrations, distinct structures and also their broad anti-tumor 
activity and low toxicity towards normal cells (79). One of the proposed mechanisms to 
explain the selectivity of these compounds against malignant cells is the upregulation of the 
expression of death receptors and their ligands specifically in leukemic cells, leading to 
activation of the extrinsic and intrinsic apoptotic pathway, not observed in normal 
hematopoietic cells (89). Another possibility for the selectivity of these compounds against 
tumor cells is upregulation of the cell cycle inhibitor gene p21 in transformed cells, that leads 
to cell cycle arrest (74). Therefore, HDACi which have anti-angiogenic potential (72) and may 
lead to induction of growth arrest, apoptosis, autophagy and differentiation of transformed 
cells (42) can be used as cancer therapeutics. To date, several HDACi, due to their proved 
anti-cancer potential, have been introduced into clinical trials for the treatment of 
hematological malignancies and solid tumors (90). 
 
7. Classes of HDACi: 
HDACi based on their chemical structures are divided into four groups: short chain fatty acids 
(or aliphatic acids), benzamides, cyclic peptides (the most structurally complex group) and 
hydroxamic acids (74) (Figure 6). In parallel, based on the specificity, these compounds are 
divided into pan-HDACi which inhibit the activity of both class I and II HDACs such as 
Vorinostat, Belinostat, Panobinostat and Trichostatin A (TSA) or selective HDACi, as 
Entinostat which exclusively inhibits class I HDACs (80). Due to the diverse cellular functions 
of HDACs, it is unclear which of the two broad groups of HDACi provide the best clinical 
benefit and optimum toxicity profile (72). 
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7.1  Short-chain fatty acids (aliphatic acids): 
The short chain fatty acids or aliphatic acids, which are the smallest and simplest types of 
HDACi, include n-butyrate, Phenylbutyrate and Valproic acid (VPA) with the activity seen at 
milimolar concentrations.  Owing to the high concentrations (mM) required to inhibit HDAC 
activity, these agents are not ideal for clinical use. Butyrate is a product of fermentation by 
intestinal micro flora in the colon. It was actually identified as the first compound, with 
HDACi activity (91, 92). 
 
7.2  Benzamides: 
The compounds belonging to this class contain a benzamide moiety. MS-275 is a member of 
this class, in which the HDACi activity is accompanied by induction of p21 expression and 
cell cycle arrest in G1 phase and induction of differentiation in association with the blockage 
of mTOR signaling (93). In a study conducted in 1999, MS-275 was orally administered to 
nude mice xenografted with 8 human cell lines. Seven out of 8 tumor cells, including gastric, 
cervix, ovary, pancreatic, lung, colorectal cancer and leukemia showed growth inhibition (94). 
This HDACi has isoform-specific inhibition activity (acts more on HDAC1/2); however, it is 
less potent than other HDACi. Approximately 9 years later, in 2008 a new family of 
benzamide derivatives HDACi was identified, which is less toxic in comparison with 
hydroximates and possesses class I specific inhibition. These HDACi are known as pimelic 
diphenylamide. Compound 106 was one of the first HDACi belonging to pimelic 
diphenylamides, with the inhibitory activity against class I HDACs, with the preference 
toward HDAC3 (95). Kinetic studies indicated that 106, is a slow, tight-binding compound 
with slow On/Off inhibitory mechanism, while hydroximates are fast On/Off HDACi.  
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Most recently, a new HDAC3 selective inhibitor (known as RGFP966) has been identified that 
is a derivative of pimelic diphenylamide family. Actually it is an N-(o-amino phenyl) 
carboxamide HDAC inhibitor. In a biochemical assay, it has been demonstrated that this 
compound has an inhibitory effect against HDAC3 with an IC50 of 0.08 μM and no other 
inhibition toward any other HDACs at concentrations up to 15 μM (96). This class of HDACi 
provides the possibility to study the role of HDAC3 in cancer. In chapter III the effects of this 
HDACi (RGFP966) on APL cells will be explained. 
 
7.3  Cyclic peptides: 
This class which is the most complex class of HDACi includes Apicidin and Depsipeptide. In 
November 2009, Depsipeptide or FK228, also known as Romidepsin, was FDA approved for 
the treatment of CTCL (74). This compound works in nanomolar ranges as a potent inhibitor 
of class I and class II HDACs. During the screening for identifying compounds that can 
selectively reverse the phenotype of ras transformed cells, Romidepsin was isolated from the 
fermentation broth of a gram-negative, coccobacillus Chromabacterium violaceum strain by a 
pharmaceutical company in Japan. In a study which was conducted by Nakajima et al, it has 
been shown that Romidepsin caused the cell cycle arrest at both G1 and G2/M phases and 
induced the apoptosis in CTCL patients. They also demonstrated that this compound led to 
accumulation of acetylated histones (H1, H2A, H2B, H3, and H4) in the cell, and established 
its role as a novel HDACi (97). Another HDACi belonging to cyclic peptide, is Apicidin with 
a broad spectrum of antiproliferative activity against a variety of cancer cell lines, and it has 
been demonstrated that HL60 cells treated with Apicidin, showed decreased number of viable 
cells, concomitant with progressive accumulation of hyperacetylated histone H4 (98). 
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7.4  Hydroxamic acids: 
In 1976, around 10 years after discovery of n-butyrate as an HDACi, the anti-fungal 
compound TSA was isolated from metabolites of strains of Streptomyces hygroscopicus. TSA 
was the first hydroxamic HDACi found to inhibit HDACs (99). This compound could induce 
differentiation of Friend cells leading to cell cycle arrest of rat fibroblasts. Since 
administration of TSA caused accumulation of acetylated histones in a variety of cell lines, it 
was determined as a potent HDACi (99). TSA has activity in nano molar concentrations but 
has also undesirable toxic side effects. In 1996, a second generation of hybrid polar compound 
was made and was called Suberoyl Amino Hydroxamic acid (SAHA), which was a potent 
inducer of differentiation of murine erythroleukemic cells (100). Less than two years later, the 
same group of researchers, reported the SAHA as a potent HDACi, which could lead to 
hyperacetylation of H4 (101). Indeed SAHA was the first HDACi that has been approved by 
U.S. FDA for the treatment of relapsed and refractory cutaneous T-Cell lymphoma (CTCL) 
(102). SAHA is also known as Vorinostat in the clinics or Zolinza, which appears to be very 
potent at micro molar concentrations and is a pan-HDACi which targets both HDAC class I 
and class II (103). There are other HDACi which belong to hydroxamic acid group such as 
Belinostat (PXD101) Panobinostat (LBH589), and Givinostat (ITF2375) which are all pan-
HDACi (80). 
 
Almost all of the HDACi which have been discovered or synthesized till now, are acting in a 
reversible manner, with the exception of Trapoxin and Depudesin, two HDACi belonging to 
cyclic tetrapeptides family that bind covalently to epoxy ketone group and irreversibly inhibit 
the enzymatic activity of HDACs (65). 
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Figure 6. Structure of histone deacetylase inhibitors. 
 
8. Mechanisms of action of HDAC inhibitors: 
HDACi mediate cell death, cell cycle arrest or differentiation, through different pathways. 
 
8.1  Effects on the cell cycle: 
Low concentrations of HDACi predominantly induce G1 arrest, while high concentrations 
induce both G1 and G2/M arrests (104). Several HDACi induce the cell cycle arrest at G1 by 
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the upregulation of cyclin-dependent kinase inhibitor p21 (105). HDACi in normal and 
transformed cells can induce arrest at G2/M stage of the cell cycle. Due to the lack of a 
functional G2 checkpoint in transformed cells they undergo apoptosis, while the normal cells 
pass through DNA repair and enter M phase, perhaps explaining the ability of HDACi to cause 
selective cell death of tumor cells. HDACi induce G1 arrest even in cells without p21, which is 
feasible through induction of other CDK inhibitors that cause cell cycle arrest, such as p15 and 
p27.  HDACi can also lead to Rb dephosphorylation. Dephosphorylation of Rb blocks E2F 
transcriptional activity (target genes required for G1 progression and G1/S transition) through 
the downregulation of cyclins (106). In 2000, Kim et al, investigated the mechanism of cell 
cycle arrest at G1 in human cervix carcinoma HeLa cells. They demonstrated that treatment of 
HeLa cells with TSA mechanistically led to histone hyperacetylation followed by growth 
arrest in G1, as well as hypophosphorylation of Rb. Upon TSA treatment, amount of cyclin E 
and the CDK inhibitor p21 increased strikingly, while that of cyclin A decreased. Induction of 
p21 and reduction of cyclin A correlated well with the decreased CDK2 activity and cell cycle 
arrest (107).  
HDACi can inhibit the spindle assembly checkpoint through disruption of spindle checkpoint 
proteins such as BUBR1 and CENP-F, leading to transient arrest of cells at prometaphase, 
followed by aberrant mitosis such as missegregation and loss of chromosomes, resulting in 
cell death by either apoptosis or mitotic cell death/catastrophe (72). 
HDACi can induce mitotic defects through the aberrant acetylation of histones in 
heterochromatin domains. Newly replicated chromatin contains acetylated histones, which are 
deacetylated during or after DNA replication. Upon administration of TSA, histones in newly 
synthesized chromatin remain acetylated, and cause disruption of the structure and function of 
the centromere and the pericentric heterochromatin, with loss of binding to heterochromatin 
binding proteins (106). 
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8.2  Effects on DNA repair: 
When HDACi inhibit the activity of HDACs, the hyper acetylated DNA cannot be protected in 
the form of condensed chromatin and will be exposed to radiation, cytotoxic drugs, reactive 
oxygen species (ROS) or UV. Therefore, these events promote the generation of DNA double-
strand breaks (108). In a study conducted by Robert et al, it has been shown that inhibition of 
class I and II HDACs by VPA in yeast influences on the DNA damage response through: i) 
counteracting the checkpoint activation (Mec1 in yeast, orthologue of human ATR); ii) 
double-strand break processing in G2/M and iii) acetylation and degradation of enzymes 
involved in DNA-double strand break repairs, through the autophagy (109). Accumulation of 
ROS after the treatment with HDACi leads to oxidative stress and subsequent apoptosis (102). 
 
8.3  Effects on extrinsic and intrinsic apoptotic pathways: 
The extrinsic apoptotic pathway is initiated by the binding of death receptors, such as Fas, 
tumor-necrosis factor receptor 1 (TNFR1) and TNF-related apoptosis-inducing ligand receptor 
(TRAIL-R)  to their ligands, including FasL, TNF and TNF-related apoptosis-inducing ligand 
(TRAIL), which leads to activation of caspase 8 and 10. HDACi induce the extrinsic pathway 
of apoptosis through the induction of death receptors and their ligands in transformed cells. 
For instance, Insinga et al. demonstrated that VPA induced TRAIL and DR5 in the mouse 
model of APL, and this induction was limited to transformed cells (110). 
The intrinsic apoptotic pathway, which is mediated by mitochondria, is induced by HDACi in 
transformed cells by releasing cytochrome c from mitochondria and activation of Caspase 9. 
HDACi induce the intrinsic apoptotic pathway by upregulation of pro-apoptotic proteins of 
Bcl-2 family or/and through reduction of anti-apoptotic proteins (106). 
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In addition, HDACi through inhibition of Hypoxia inducible factor (HIF) have anti-angiogenic 
effects and they impact on ubiquitin-proteasome system. The summary of pathways in which 
HDACi have an impact is shown in Figure 7 (72). 
 
 
 
 
Figure 7. Impact of HDAC inhibitors on malignant cells through different pathways. HDAC 
inhibitors inhibit the deacetylation activity of HDACs. Thus, hyperacetylation of histones alter 
chromatin activity and deregulations of deacetylation of several non-histone proteins have effects on 
cell cycle, angiogenesis, apoptosis and so on. Taken together, as most of these pathways are impaired 
in tumor cells they can be targeted by HDAC inhibitors. Modified from Khan et al, Immunology and 
cell biology, 2012 (72). 
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9. Molecular pathogenesis of Acute Promyelocyte Leukemia: 
APL is characterized by hyperproliferation of immature granulocytes, known as 
promyelocytes. According to the French-American-British (FAB) classification, APL belongs 
to the M3 subtype of AML and accounts for around 5-10% of all AML cases (111). APL is 
often associated with chromosomal translocations which lead to the fusion of the gene 
encoding for the retinoic acid receptor alpha (RARα), a master regulator of myeloid 
differentiation, located on chromosome 17, and a number of alternative genes, for instance; 
promyelocytic leukemia (PML), promyelocytic leukemia zinc factor (PLZF), nucleophosmin 
(NPM), nuclear mitotic apparatus (NuMA), signal transducer and activator of transcription 5b 
(STAT5b) (Figure 8). 
 
Figure 8. Chromosomal translocations associated with APL result in fusion proteins. 
Modified from Melnick et al, Blood, 1999 (112). 
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In more than 95% of the cases, APL is caused by a balanced chromosomal translocation 
t(15;17)(q22;q21), which juxtaposes the genes encoding for the promyelocytic leukemia 
(PML) on chromosome 15 to the RARα (113, 114). PML-RARα recruits different chromatin 
modifier factors, such as HDAC complexes, like NCoR (115) and SMRT (116) and DNA 
methyltransferases (DNMTs) (117) to the promoter of RARα target genes and 
transcriptionally silence them, leading to alteration in chromatin structure and the myeloid 
differentiation block (118, 119).  
In 5% of APL cases, there is a chromosomal translocation involving RARα on chromosome 
17 that translocates to PLZF on chromosome 11. PLZF encodes a transcription repressor that 
is a member of the POK family of proteins. While APLs with PML-RARα fusion protein are 
responsive to pharmacological doses of RA, APLs with t(11;17) do not respond or respond 
poorly to RA (120). In several studies, researchers made an attempt to discover the reason 
behind this phenomenon (resistance of PLZF-RARα to RA). Results of these studies suggest 
that similar to PML-RARα, PLZF-RARα recruits corepressor complexes containing HDACs. 
PML-RARα has a binding site for NCoR repressor complex in its RARα moiety that is called 
CoR box, while PLZF-RARα contains two NCoR binding sites: the first is RA sensitive and 
maps within the CoR box of RARα, the second is RA resistant and is found at the amino 
terminal of PLZF, acting as a stronger repressor compared to PML-RARα (115). 
In contrast to most cancers, mutations of p53 are rare in APL patients, but dysfunctionality of 
p53 is imposed by the cooperation of PML-RARα with class I HDACs, which deacetylate p53 
and induce its degradation through the MDM2-proteosome mediated pathway (121). HDACs 
from class I (HDAC1, 2 and 3) have been found associated with PML-RARα paving the way 
for the use of HDACi in APL treatment. Disruption of PML nuclear bodies (PML-NBs), 
which have been implicated in a variety of cell functions is mediated by PML-RARα (122). In 
48 
 
the mouse model of APL, the disease can be initiated by the expression of oncogenic fusion 
protein in hematopoietic stem cells or progenitors. This stage of the disease is known as pre-
leukemic stage which leads to the onset of the disease after a long latency (full leukemic 
stage), suggesting the monoclonality or oligoclonality of APL and it faithfully recapitulates 
clinical and morphological symptoms of human APL (123). Analysis of different transgenic 
mice expressing AML-fusion proteins indicates that even though these fusion proteins have 
oncogenic potential, additional genetic and/or epigenetic lesions are required for progression 
to full leukemic stage. In APL the first hit which confers the oncogenic potential to cells is 
PML-RARα and HDACs are among presumptive second hits (79). There are emerging 
evidences showing that alterations causing global chromatin changes such as mutations in 
genes encoding: DNA methylation and histone modification enzymes occur at the pre-
leukemic stage, and the pre-leukemic HSCs may survive upon chemotherapy and by gaining 
additional mutations they will play the role of putative reservoir for relapsed disease, while 
mutations in proliferative genes occur later on (124). 
 
10. APL and targeted therapy: 
APL is the first malignancy cured by targeted therapy. All-trans retinoic acid (ATRA), also 
known as retinoic acid (RA), leads to the terminal differentiation of leukemic cells by 
reversing the PML-RARα mediated transcriptional inhibition, through the degradation of 
PML-RARα and substitution of co-repressor complexes with co-activators through 
conformational changes. Further studies have shown a prerequisite for chromatin repression 
by PML-RARα through its binding to the PU.1 (a master regulator of hematopoietic 
differentiation process) (125). The first studies for the treatment of APL with ATRA began in 
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1980s. Following treatment with ATRA alone, patients experienced induction of an ATRA-
resistance relapsed APL and for this reason for the previous 3 decades was used in 
combination with chemotherapy (126, 127). Arsenic trioxide (ATO or As2O3), which was first, 
approved in relapsed APL prompts the apoptosis of APL cells and as single agent cures 
approximately 70% of de novo APL. ATRA and ATO, which are known as the two most 
important drugs for early diagnosed APL, both target the stability of PML-RARα, ATRA 
through the RARα moiety and ATO via PML moiety (128). However, a recent study 
demonstrated that differentiation of leukemic blasts stimulated by ATRA is neither sufficient 
nor necessary for the treatment of APL, since the administration of ATRA in PLZF-RARα 
driven APL that is known as ATRA-resistant variant of APL leads to the differentiation of 
leukemic blasts but not to the remission of the disease or in the relapsed PML-RARα driven 
APL patients which have been became resistant to ATRA due to the suboptimal 
concentrations of drug, the cell proliferation and tumor growth will be sustained even if 
differentiation is ongoing. Therefore instead of therapy aimed at inducing differentiation, 
looking for therapies which target self-renewal ability of cancer cells can be more efficient 
(129). Genome-wide epigenetic studies revealed that treatment of APL with pharmacological 
doses of ATRA induces an increase in histone H3 acetylation at PML-RARαbinding sites or 
at nearby target genes. It has been suggested that this results in the release of PML-RARα 
from the genes which are important for normal hematopoietic differentiation (17). 
 
11. APL as a paradigm for epigenetic therapy: 
Since APL is the best-known and most studied example of a hematological malignancy in 
which a causative role for HDACs has been clearly demonstrated, it represents a perfect model 
to validate the concept of epigenetic therapy. As it was described before, APL treatment with 
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retinoic acid (RA) represents the first example of: i) targeted therapy, ii) transcription therapy 
and, iii) differentiation therapy in which the drug restores the normal program of cellular 
differentiation rather than killing leukemic cells as conventional chemotherapy would do. 
Working as an altered transcription factor, PML-RARα is able to alter the epigenetic 
landscape of its target cells, causing a differentiation block at the promyelocytic stage. RA 
reverts the action of the fusion protein and allows terminal differentiation of the leukemic 
cells, and in combination with other agents (chemotherapy, arsenic) leads to definitive cure of 
the majority of APL patients. Although PML-RARα recruits HDACs for its action at target 
genes, the interplay of PML-RARα with epigenetic modifiers is more complex than previously 
thought (17). Experimental studies aimed at dissecting the role of individual HDACs in APL 
development and maintenance have shown that transplantation of mice with lineage negative 
(Lin-) PML-RARα expressing cells knocked down for Hdac1 or Hdac2, caused an accelerated 
leukemia development by shortening the pre-leukemic phase. Importantly, a dramatic 
expansion of a subpopulation of pre-leukemic cells with the features of leukemia 
initiating/stem cells (LICs) could be detected as soon as 40 days post-transplantation of Lin- 
cells expressing PML-RARα and knocked down for Hdac1, suggesting that HDAC1 is 
required to control the self-renewal of LICs. Strikingly, in frank leukemic cells knockdown of 
the same Hdacs slows down leukemia growth, demonstrating that HDAC1/HDAC2 play 
different roles in APL initiation and maintenance. Complementing these studies, the HDAC 
inhibitor Valproic acid or VPA (mainly acting on class I HDACs) was shown to behave 
differently at the pre-leukemic vs. the leukemic stage, mimicking the Hdac1 knockdown 
phenotype (87). Moreover, in established leukemia, VPA showed a different effect on the bulk 
of tumor cells vs. LICs, being mostly effective on the bulk of APL blasts and having only a 
mild effect on LICs (130). From these studies, it therefore appears that HDACs can not only 
play different roles at different stages of tumorigenesis, but also have different biological 
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effects in different tumor cell subtypes (LICs vs. bulk). Since epigenetic changes are important 
and required for normal cellular differentiation, it is not surprising that the effect of epigenetic 
drugs depends on the targeted cellular population.  
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Aims of the project 
As epigenetic aberrations are found in almost all AML subtypes and these modifications are 
reversible, it is not surprising that drugs targeting epigenetic marks and the chromatin modifier 
enzymes are being developed and used to treat the disease. Thus, targeting of epigenetic 
aberrations is becoming an established approach for the treatment of AML patients. Several 
epigenetic drugs have been approved for clinical use, and others are in various stages of 
development. As an example of epigenetic therapy, HDACi that target multiple HDACs are 
effective for the treatment of CTCL. 
Acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia (AML), has been 
deeply characterized. In particular PML-RARα, the most frequent chimeric protein 
(approximately covers 95% of APL cases) responsible for the occurrence of APL, has been 
extensively studied and it has been identified as the first disease in which the involvement of 
HDACs in the pathogenesis of the disease has been implicated.  
Since epigenetic drugs have single agent efficacy only in selected hematological malignancies, 
further studies aimed at better understanding of the epigenetic alterations and of epigenetic 
enzymes in different cancers are needed. Our group is studying the role of HDACs in the 
pathogenesis of APL. The group has previously shown that HDAC1 and to a lesser extent 
HDAC2 have a dual role in APL: oncosuppressor in establishment, oncogene in maintenance 
of the disease, and that HDACi can have different effects on bulk vs. leukemic stem cells.   
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Actually we believe that a better understanding of the role of individual HDACs in leukemia 
paves the way for developing more efficacious treatments with selective epigenetic drugs.  
Taken together, my project has focused at studying the role of HDAC3 in the development of 
APL, and in the maintenance of the disease. To achieve our goals, we used APL as a model 
system, using a selective knock-down of Hdac3 in primary murine hematopoietic progenitors 
to study the biological effects of the knock-down on APL initiation in vitro and in vivo. Then 
we took advantage of using the selective knockdown of Hdac3 in primary APL cells to 
investigate the biological effects of the knockdown in APL maintenance.  In this study HDACi 
(RGFP966) with selectivity against HDAC3 has been used, to investigate the feasibility of 
targeting HDAC3 for clinical use. To further investigate the role of HDAC3 in more 
hematological malignancies, its role has been systematically studied in AML driven by MLL-
AF9 in collaboration with Prof. Johannes Zuber’s group and in lymphoma driven by Eμ-myc 
model in collaboration with Prof. Ricky Johnstone’s group. 
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Materials & methods 
1. Plasmids: 
pRETRO-SUPER (pRS): a modified retroviral vector in which the cDNA for puromycin 
selection marker had been replaced with the one encoding for enhanced green fluorescence 
protein (eGFP). The shRNA-based plasmids were generated by cloning the synthetic 
oligonucleotides targeting the mRNAs for firefly luciferase (Luc) as the control and Hdac3 
into the modified pRS. The shRNA sequences (Table 1) are in the format: target sequence 
sense (underlined), loop-target sequence antisense (underlined). 
shRNA name Sequence 
CTRL (Luc) GATCCCCGTACGCGGAATACTTCGATTCAAGAGATCGAAGTATTCCG
CGTACGTTTTTGGAAA 
Hdac3-KD GATCCCCGTGGCTCTCTGAAACCTTATTCAAGAGATAAGGTTTCAGAG
AGCCACTTTTTGGAAA 
Table 1. shRNA sequences used in the experiments with pRetroSuper vector. 
 
Inducible Tet-On shRNAmiR30 dual vector system: the vectors have been generated in 
collaboration with R.W Johnstone’s and J. Zuber’s lab from (The Sir Peter MacCallum 
Department of Oncology, University of Melbourne and Institute of Molecular Pathology, 
Vienna, Austria), this system represents a better experimental set-up allowing a more thorough 
functional analysis of the role of HDAC3 in APL and  precise tracking of both retrovirally 
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transduced cells and shRNA induction, through two fluorescent reporters; dsRed which shows 
the expression of shRNA and Venus which shows the transduction of vector into cells (Figure 
9). 
 
 
Figure 9. Schematic representation of an inducible Tet-On miR30 dual color vector (All-in-one 
system). An inducible shRNA expression system that enables precise tracking of retroviral 
transduction and shRNA induction through two fluorescent reporters. In TRE-dsRed-miR30/shRNA-
PGK-Venus-IRES-rtTA (TRMPV), upon induction by doxycycline the TRE drives expression of a 
dsRed fluorescent protein and shRNA, whereas the phosphoglycerate kinase (PGK) promoter drives 
constitutive expression of the yellow-green fluorescent protein Venus. The vector is constructed in the 
pQCXIX self-inactivating (SIN) retroviral backbone. 
 
In TRE-dsRed-miR30/shRNA-PGK-Venus-IRES-rtTA or TRPMV vector, while 
phosphoglycerate kinase (PGK) promoter drives constitutive expression of Venus fluorescent 
protein, Tetracyclin-responsive element (TRE) drives expression of dsRed fluorescent protein 
and microRNA (miR30)-embedded shRNA, upon administration of doxycycline. In fact we 
had two types of inducible vectors, the “All in one system” depicted in Figure 9 and the 
“Double system” (Figure 10). In the double system, cells were first infected with reverse-
tetracyclin transactivator (rtTA) and transduced cells were selected by hygromycine and then 
they were infected with TRMPV vector, which contains miR30-embedded shRNA. The 
shRNA sequences used in these types of vectors can be found in Table 2. 
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Figure 10. Map of inducible TRMPVIN vector or double system. In this system rtTA expression is 
enforced in a vector which contains hygromycin selection marker and miR30-embeded shRNA 
expression is enforced in the second vector by administration of doxycyclin. 
 
Targeting sequences for short hairpin RNA (shRNA)-miR30 constructs against murine 
HDAC3 (RefSeq NM_010411) were identified using Designer of Small Interfering RNA 
(DSIR) algorithm. The top-ranked shRNAs were used to create 10 miR30 sequences (97mer, 
Sigma-Aldrich) and these were cloned into the XhoI/EcoRI sites of TRMPVIN plasmid 
following the generation of approximately 110-bp shRNA-miR30s by amplification of 97 
mers using 5′miR30-XhoI (CAGAAGGCTCGAGAAGGTATATTGCTGTTGACAGTGAGCG) and 
5′miR30-EcoRI (CTAAAGTAGCCCCTTGAATTCCGAGGCAGTAGGCA) primers. The miRNA 
oligomer sequences are in the format: miR-30 context-sense (underlined)-loop-antisense 
(underlined). 
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shRNA name sequence 
Tet-On-Scrambled 
shRNAmiR30 
TGCTGTTGACAGTGAGCGATCTCGCTTGGGCGAGAGTAA
GTAGTGAAGCCACAGATGTACTTACTCTCGCCCAAGCGA
GAGTGCCTACTGCCTCGGA 
Tet-On-Hdac3 
shRNAmiR30 
TGCTGTTGACAGTGAGCGCTAAGAAGATGATCGTCTTCAA
TAGTGAAGCCACAGATGTATTGAAGACGATCATCTTCTTA
TTGCCTACTGCCTCGGA 
Tet-On-Renilla 
shRNAmiR30 
TGCTGTTGACAGTGAGCGCAGGAATTATAATGCTTATCTA
TAGTGAAGCCACAGATGTATAGATAAGCATTATAATTCCT
ATGCCTACTGCCTCGGA 
Table 2. Sequence of shRNAs used in the experiments with Tet-On-inducible vector. 97 mer  
XhoI/EcoRI miR30-shRNA fragments are provided.  
 
2. Calcium Phosphate transfection: 
This technique can be used for both transient and stable introduction of exogenous DNA into 
mammalian cells through the formation of calcium phosphate-DNA precipitates.  
The day before transfection the packaging cells (in this study packaging ecotropic phoenix 
cells which were purchased from ATCC) were seeded at the density such that the day of 
transfection they were 50% to 60% confluent. Phoenix cells were maintained in Dulbecco 
modified eagle medium supplemented with 10% fetal bovine serum (FBS), 2 mM of L-
glutamine and antibiotics. For the transfection two solutions were prepared, the first one 
contained DNA of pRS (10μg/ 100mm plate) and DNA of packaging plasmid, pCL-Eco 
(5μg/100mm plate), 61μL of CaCl2 and H2O in the final volume of 500μL; the second solution 
contained (500μL/100mm plate) of 2X Hepes-buffer (HBS). The first solution was slowly 
added drop wise to the 2X HBS while bubbling air through it with a Pasteur pipette. After 10-
20 minutes the formed DNA-calcium precipitates were added to the media of the cells. The 
cells were incubated at 37˚C in a humidified CO2 incubator for 12 hours, and then the media 
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was removed and replenished with fresh one. Forty-eight and 72 hours post-transfection the 
first and second viral supernatant were collected. 
 
3. Concentrating viral supernatant: 
In order to concentrate retroviral-based particles, 48 hours and 72 hours post-transfection the 
first and second viral supernatant respectively were filtrated through 0.45 μm Millipore 
syringe filters and transferred into sterile 50mL falcons, and 1 volume of cold PEG-itTM virus 
precipitation solution was added to every 4 volumes of retrovector-containing supernatant. 
Then it was refrigerated overnight at 4˚C, and the next day it was centrifuged at 1500x g for 
30 minutes at 4˚C. After centrifugation the retrovector particles appeared as a white pellet at 
the bottom of the falcon all traces of fluid was removed by aspiration and the retroviral pellet 
was resuspended 1:100 of original volume using cold, sterile PBS, aliquoted into cryogenic 
vials and stored at -80˚C.  
 
4. Immunoblots and antibodies 
Whole cell extracts were obtained by using 100μL to 200μL of sodium-dodecyl-sulfate (SDS) 
lysis buffer (2% SDS, 10% glycerol, 50mM of Tris HCL). Protein was quantified by a Bio-rad 
Bradford assay. 50μg total protein was boiled for 5 minutes at 95˚C. Protein was 
electrophorased and separated on 12% SDS-polyacrylamide gel electrophoresis (SDS-PAGE), 
transferred to  a nitrocellulose membrane (Whatman, Schleicher & Schuell) in a 1X transfer 
buffer containing 20% methanol, at 100V for 1 hour at 4˚C. Ponceau S was used for staining 
of membrane, which allows the visualizing of proteins and thus the quality of the transfer. 
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After a brief wash in water and 1% Tris-buffered Saline-Tween (TBS-T), the membrane was 
blocked in 5% milk dissolved in 1% TBS-T for 1 hour at room temperature and then probed 
with the primary antibody diluted in 5% milk 4˚C overnight. The next day, after 3 washes with 
1% TBS-T (each wash 10 minutes), membrane was incubated with the proper horseradish 
peroxide (HRP)-conjugated secondary antibody diluted in 5% milk, for 30-60 minute at room 
temperature. After 3 washes in 1% TBS-T, the bound secondary antibody was revealed by 
using the ECL (Enhanced Chemi luminescence) method. The antibodies used in this study 
were anti-HDAC3 (ab7030) and anti-Vinculin (Sigma Aldrich). 
 
5. Primary cells: 
Lin- (lineage negative) cells which are enriched for hematopoietic stem and progenitor cells 
obtained from transgenic mCGPR/PR mice, 6 to 12 weeks old (pre-leukemic cells) or from 
C57BL/6J wild-type mice (wild-type cells). The purified Lin- cells were cultured in RPMI 
supplemented with 10% FBS Stem, antibiotics, 2mM of L-glutamine and cytokines. All 
cytokines were purchased from Peprotech. Cells were maintained between 500x103-1x106 
cells/ mL. 
APL cells were produced by inoculation of transduced Lin- cells derived from 129SvEv mice, 
with PML-RARα expressing PINCO vector into syngenic irradiated mice and then the APL 
blasts were obtained from leukemic animals, as previously described (131) and cultured in 
Iscove’s Modified Dulbecco’s Medium (IMDM) supplemented with FBS (12.5%), horse 
serum (12.5%), 2mM L-glutamine, penicillin/streptomycin (1%), hydrocortisone (260ng/mL), 
β-mercapthoethanol (50µM), Amphotericine B (1%), recombinant IL-3 (2 ng/mL), IL-6 (2 
ng/mL) and stem cell factor (SCF; 10 ng/mL). 
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6. Purification of Lin- cells: 
To purify murine hematopoietic stem and progenitor cells, the negative selection system 
(StemSep® Hematopoietic Progenitor Enrichment) was used. In this system the unwanted cells 
which are the vast majority of the cells in a start cell suspension, are immunomagnetically 
labeled and bound to a magnetic column, while the desired cells which do not have the 
antibody bound to their surface will be collected in the column flow through.Usually 1-2% of 
Lin- cells will be recovered from the start mononuclear cell population. Specifically, bone 
marrow was collected from femurs and tibias of 6- to 12-week old mCGPR/PR mice, and to 
harvest the total bone marrow cells, the bones were crashed and the whole marrows were 
washed in phosphate-buffered saline (PBS); red cells were removed by incubation in red cell 
lysis buffer. Sequentially, cells were briefly blocked with rat serum, which prevents the non-
specific binding of rat antibodies to the mouse cells. This procedure takes advantage of a 
cocktail of biotinylated monoclonal antibodies directed against mouse lineage specific surface 
markers (CD5, CD11b, CD45R/B220,Gr-1, TER119 and neutrophils) and a tetrameric 
antibody complex directed against both biotin and dextran iron magnetic particles. In the last 
step of the purification procedure, the cells which were labeled with the colloid were loaded 
into a magnetic column, and therefore the lineage negative cells pool were eluted and 
collected for further analysis, while differentiated cells were sustained in the column (Figure 
11). 
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Figure 11. Schematic representation of the negative selection procedure for Lin- purification. 
Adapted fromwww.stemcell.com/en/Products/Popular-Product-Lines/EasySep.aspx 
 
 
7. Preparing retronectin coated plates: 
Recombinant human fibronectin fragment, called retronectin (Takara) favors the co-
localization of target cells and retroviruses, therefore enhancing the retroviral mediated gene 
transduction. Retronectin was diluted with 9 volume of PBS then 500μL of diluted retronectin 
was added to each well. The plate was incubated at room temperature (RT) for 2 hours, 
retronectin was then aspirated and the wells were washed once with BSA 2%, then BSA 2% 
was added for the second time to each well (500μL/well), and the plate was kept at RT for 30 
minutes. The last step was washing the wells twice with sterile PBS and then the plate was 
wrapped in parafilm in order to avoid evaporation and kept at 4˚C for the subsequent infection. 
 
62 
 
8. Infection of Lin- cells: 
Enriched hematopoietic stem and progenitor cells (Lin-) which were purified as described 
above, were maintained (500x103 to 106cells/mL)  in a medium composed of RPMI, 1% 
glutamine, 1% antibiotics, 10% FBS stem (StemSep), recombinant murine interlukine-3 (rm 
IL-3) (20ng/mL), rm IL-6 (20ng/mL) and stem cell factor (rm SCF, 100ng/mL). The day after 
purification, Lin- cells were plated (200x103 to 300x103 cells/mL) into a 24-well plates which 
were already coated with retronectin. Cells were infected simply by adding the concentrated 
retroviral supernatant (20-35μL/well) onto the cells; the plate was centrifuged for 15 minutes 
at 4˚C in 3000rpm and then incubated at 37˚C overnight. The second round of infection was 
performed the day after by adding (20-35μL/well) of concentrated retroviral supernatant to the 
cells and centrifugation for 15 minutes at 4˚C in 3000rpm. Infected cells expressed shRNA 
against the mRNA of the protein of interest and GFP as the selection marker. Therefore the 
selection of cells expressing the shRNA was done by sorting of GFP positive cells by 
fluorescence-activated cell sorting (FACS) instrument (FACSVantage instrument, BC). 
 
9. Cell proliferative potential: serial replating on methylcellulose:  
Colony forming unit assay (CFU assay) is an in vitro functional assay for enumerating 
multipotential and lineage-committed hematopoietic progenitor cells (HPCs) in bone marrow. 
Based on a study conducted by Occhionorelli et al, it has been shown that PML-RARα 
expression results in an enhanced proliferative ability of Lin- cells. While PML-RARα 
expression increased the colony-forming potential, which lasted at least eight platings, Lin- 
cells derived from wild-type mice exhausted their proliferative potential after a few platings 
(132).  A total of 5,000 sorted or unsorted (for the study with inhibitor) Lin- cells or 10,000 
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sorted APL blast were seeded in methylcellulose medium which is a semisolid medium 
(MethoCult SF M3434, Stem Cell Technology, Vancouver, BC, Canada) containing 15% fetal 
bovin serum (StemSep), 1% BSA- 10μg/mL Insulin- 200μg/mL transferrin- 50ng/mL rmSCF, 
10ng/mL rm IL-3, 10ng/mL rm IL-6 and 3U/mL rh EPO, 2-Mercaptoethanol and 2mM L-
glutamine. After 7 to 10 days of culture, colonies were scored and the cells were used for 
immunolableing, morphologic analysis and serial replating.  
 
10. Cell differentiation: analysis of cell surface markers: 
Five thousands GFP+ sorted pre-leukemic cells or 10,000 GFP+ sorted APL cells were plated 
in methylcellulose medium. After 7 to 10 days, cells were collected and resuspended in PBS 
and blocked for 30 minutes with BSA 5%, then they were immunolabeld with Ly-6A/E 
(SCA1) PE-Cy5.5 conjugated, CD117 (C.Kit) (APC conjugated), CD11b (MAC1) and Ly-6G 
(Gr-1) both PE-Cy7 conjugated, surface markers. 
SCA1 and c.Kit had emerged as a phenotypic marker of choice for identifying and isolating 
hematopoietic stem and progenitor cells.  Hematopoietic stem cells (HSC), multipotent 
progenitors (MPP), and common myeloid progenitors (CMP) express high levels of CD117. 
CD11b is expressed at variable levels on monocytes/macrophages, dendritic cells, 
granulocytes and their precursors and on Natural killer (NK) cells. This marker constitutes a 
differentiation marker expressed relatively late in hematopoiesis, and is almost undetectable 
on more primitive stem cells and precursors. The Ly-6G previously named Gr-1, is a myeloid 
differentiation marker as well; it is briefly found on monocytes during their differentiate 
pattern and mainly expressed on mature granulocytes. 
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11. Mice strains and transplantation experiments: 
Transgenic mCGPR/PR mice were generously provided by T.J. Ley (Washington University, St 
Louis, MO) and backcrossed into the C57BL/6J strain. 129SvEv mice were bought from the 
Jackson laboratory. 
For lineage-negative (Lin-) transplantation experiments, lethally irradiated (9Gy) C57BL/6J 
mice, 12 to 14 weeks old, were inoculated intravenously with 300,000 GFP+-transduced Lin- 
cells, together with 500,000 spleen cells obtained from a wild type (WT) mouse (to transiently 
support the new hematopoiesis). 
For leukemia transplantation, GFP+-transduced leukemic cells were injected intravenously 
(200,000 cells/mouse) into 129SvEv recipient mice. Generation of APL leukemias used for 
investigating the role of HDAC3 in full leukemic stage has been described previously (131). 
 
12. Monitoring of transplanted mice: 
Mice that were inoculated with the above mentioned cells were checked periodically for 
clinical signs of disease (by inspection and periodic blood analysis using the AcTTM 5diff 
Beckman Coulter, Brea, CA). Long-term reconstitution of the hematopoietic compartment was 
assessed by scoring the percentage of GFP+ cells in peripheral blood at least 4 months after 
transplantation.Blood samples were obtained from mouse tail vein prepared for flow 
cytometric analysis by red cell lysis and then FACS analysis was performed using BD, 
FACSCantoII BD, FACSDiva Software V6.1.1.). Mice were euthanized by CO2 inhalation 
when they became detectably ill. The survival rate was calculated using the Kaplan-Meier 
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method. All these procedures involving animals were done in accordance with national and 
international laws and policies. 
 
13. Quantitative polymerase chain reaction (Q-PCR): 
In order to quantify the HDAC3 mRNA relative levels upon functional knockdown, RNA was 
extracted from desired transduced-sorted Lin- or APL cells, isolated with RNeasy Mini kit 
(QIAGEN, Valenica, CA)eluted RNA was quantified by spectrophotometer (ND1000 
NanoDrop)  and reverse transcribed to cDNA. Ten to 20ng of cDNA were used to perform 
QPCR using SYBER green reaction mix (Perkin Elmer, Boston, MA). mRNA levels were 
normalized against GAPDH mRNA. The sequences of the primers used in this study are listed 
in the table 3. 
Primers name Sequence (5′-3′) 
mHDAC3fw 
mHDAC3rw 
AGCTGGACACCCAATGAAAC 
TATTGGTGGGGCTGACTCTC 
GAPDH fw 
GAPDH rw 
AACTTTGGCATTGTGGAAGG 
CACATTGGGGGTAGGAACAC 
Table 3. Primers for quantitative PCR used in this study. 
 
14. Histone deacetylase inhibitors (HDACi): 
The HDACi RGFP966 was kindly given to us by Prof. R.W. Johnstone’s lab taken from 
Repligen Corporation. This compound is an analog of previously published compounds (133) 
but has different HDAC inhibition selectivity. In purified enzyme assays, RGFP966 had the 
following HDAC inhibition IC50= 0.08 mM for HDAC3: and IC50 >15mM for HDAC1 and 
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HDAC2. RGFP966 was diluted in DMSO (10mM) prior to treatment of Lin- or APL cells at 
concentrations depicted in Figure 27 and Figure 30 respectively. 
 
15. Treatment with HDACi : 
Lin- cells derived from wild type or mCGPR/PR mice and APL cells were treated in vitro with 
different concentrations of the HDAC3-selective inhibitor, RGFP966 (Repligen), then plated 
in methylcellulose for C.F.U assay and mature and immature populations were defined based 
on cells morphology 
 
16. May-Grünwald-Giemsa staining: 
The cells collected from methylcellulose plates were spun onto a cytological slide by using a 
cytospin centrifuge (Cytospin™ 4 Cytocentrifuge). Cytospins were stained using the May-
Grünwald-Giemsa staining method. The fixed cells were stained for 8 minutes in May-
Grünwald stain, then slides were washed sequentially 3 times in distilled water, kept for 40 
minutes in Giemsa stain and diluted with 19 volumes of distilled water. After this step the 
cytological slides were rinsed again 3 times in distilled water and air-dried. For long time 
storage, a cover slip was attached to the slides by Eukitt ® mounting medium, which is an 
adhesive and specimen preservative that can be used manually and in automated cover 
slipping equipment. Mature and immature populations were defined based on their 
morphology, by scoring the percentage of mature and immature cells in each condition. In 
particular, the prevalence of mature and immature cells was analyzed morphologically in 
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cytological slides in each case and the absolute percentage of mature cells was reported. At 
least 300 cells were scanned for each case. 
 
17. Mouse tail vein sampling: 
Prior to take the sample to dilate the blood vessel, the mouse tail was warmed for some 
minutes. Then the lateral tail vein was used and 80μL of blood obtained per sample. Before 
collecting the samples 20μL of 1mM EDTA had been added into 1.5mL tube in order to 
prevent blood coagulation. Applying finger pressure on the soft tissue stopped blood flow. A 
finger was placed at the blood-sampling site for approximately 30 seconds before the animal 
was returned to its cage. 
 
18. Blood cell staining for the FACS analysis: 
1mL of red cell lysis buffer was added to each 100μL of blood sample, and then incubated at 
room temperature for 10 minutes. After incubation it was centrifuged for 5 minutes at 
5,000rpm, and the white pellet resuspended in the blocking serum (BSA 5%). After 30 
minutes incubation at 4˚C, the cells already resuspended in blocking serum were stained with 
the desired antibody and kept at 4˚C for 30 minutes, after washing the unbound antibody by 
PBS, the cells were fixed with formaldehyde 2% and were used for the FACS analysis (BD, 
FACSCantoII BD, FACSDiva Software V6.1.1.) 
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19. Statistical analysis: 
Statistical analyses were performed using the Fisher exact test (GraphPad software) unless 
otherwise specified. Statistical analysis of the Kaplan-Meier survival curves were done using 
the log-rank test (Prism 4.0 software). 
 
20. Contents of general buffers used in this study: 
20.1. Phosphate-Buffered Saline (PBS), pH 7.4: 
137 mM NaCl 
2.7 mM KCl 
8.1 mM Na2HPO4  
1.76 mM KH2PO4
 
 
20.2. Tris-Buffered Saline (TBS)-Tween: 
150 mM NaCl 
2.7 mM KCl 
25 mM Tris base 
0.1% Tween 20 
 
20.3. Tris-Acetate-EDTA (TAE): 
40 mM Tris acetate 
1 mM EDTA pH 8. 
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20.4. Urea lysis buffer: 
8 M Urea 
25 mM Tris-HCL pH 6.8 
1 mM EDTA 
10% glycerol 
 
20.5. Resolving gel mix (1 gel at 12%): 
Acrilamide/Bis-acrylamide solution 30 %: 2.52 mL for 12% gel 
Tris-HCl, pH 8.8 (1.5 mL) 
ddH2O (1.7 mL) 
SDS 10% (60 μL) 
APS 10% (50 μL) 
TEMED (2 μL) 
 
20.6. Stacking gel mix (1 gel): 
Acrilamide/Bis-acrylamide stock solution – 30%: 0.8 ratio at 30% (0.52 mL) 
Tris-HCl, pH 6.8 (1.25 mL) 
ddH2O (3.10 mL) 
SDS 10% (50 μL) 
APS 10% (50 μL) 
TEMED (5 μL) 
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20.7. Laemmli loading buffer (5X): 
100mM Tris-HCl pH 6.8  
20% Glycerol 
2% SDS 
5% β-mercaptoethanol 
 
20.8. Western blot transfer buffer: 
25 mM Tris base 
192 mM Glycine 
20% Methanol 
 
20.9. Western blot Stripping buffer: 
62.5 mM Tris-HCl, pH 7.6 
2% SDS 
100 mM β-mercaptoethanol 
 
20.10. Red cell lysis buffer: 
150 mM NH4Cl 
10 mM KHCO3 
0.1 mM EDTA 
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  Results 
Previous studies in our laboratory have shown that the interplay of PML-RARα with 
epigenetic modifiers is more complex than previously thought. Indeed, knock-down (KD) of 
Hdac1/Hdac2 in PML-RARα transgenic mice accelerates leukemia development, 
accompanied by a dramatic expansion of a subpopulation of pre-leukemic cells  with  the  
property  of  leukemia initiating/stem cells (LICs), suggesting that HDACs are required to 
control the self-renewal of LICs. This event was not restricted only to APL because 
lymphomagenesis driven by deletion of p53 or, to a lesser extent, by c-myc overexpression, 
was also accelerated by Hdac1 knock-down. Strikingly, in established leukemic cells knock-
down of the same HDACs slows down leukemia growth, demonstrating that HDAC1/HDAC2 
play different roles in APL initiation and maintenance (87). Overall, our data suggest that 
different HDACs have different roles in different stages of the disease, and imply that more 
studies are needed to systematically dissect the role of individual HDACs, at different stages 
of tumorigenesis (initiation vs. maintenance), in different tumor compartments (bulk vs. cancer 
stem cells) and in different tumor cell types. Thus, these results prompted us to further 
investigate the role of other class I HDACs in APL development, and this study addresses the 
role of HDAC3 in APL. APL is characterized by induction of cell proliferation and a block in 
myeloid differentiation. Direct action of PML-RARα is apparently involved in both events and 
this is in part due to its association with HDACs, although HDACs can affect both biological 
processes independently of PML-RARα. Therefore, we investigated the role of HDAC3 in 
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these processes in the pre-leukemic and leukemic stages of APL through a selective knock-
down approach. The murine model of APL we used is the mCGPR/PR mouse model in which 
PML-RARα is expressed under the control of the cathepsin G promoter (123). To study the 
biological roles of HDAC3 in APL we used the functional knock-down approach. To achieve 
this aim, shRNA-based plasmids were generated as described in chapter II of this dissertation, 
by ligating synthetic oligonucleotides targeting HDAC3 and the control firefly luciferase 
(LUC) mRNAs into a modified pRetroSuper vector in which the cDNA for puromycin 
selection was replaced with the one encoding enhanced GFP (eGFP). 
 
 
1. Effect of Hdac3 knock-down at the pre-leukemic stage:  
The well-characterized mCGPR/PR mouse model (123) was used as a model for PML-RARα 
driven APL. Lin- (lineage negative) cells, which are enriched in hematopoietic stem and 
progenitor cells (HSPCs) from mCGPR/PR mice, were purified and transduced with GFP-tagged 
retroviral vectors (pRetroSuper) targeting the control firefly luciferase (LUC) or HDAC3 
transcripts. FACS-purified GFP+/Lin- cells, were then analyzed in vitro and in vivo, as 
summarized in Figure 12.  
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Figure 12. Schematic depiction of experimental procedure employed to assess the role of HDAC3 
at the pre-leukemic stage. 
 
1.1 In vitro assays:  
RNA and protein analysis of GFP+/Lin- sorted cells, confirmed reduction of HDAC3 by the 
targeting shRNA constructs (Figure 13). Furthermore, Knockdown of Hdac3 had no effect on 
the expression of PML-RARα. 
 
Figure 13.Constitutive depletion of Hdac3 at pre-leukemic stage. A) Analysis of mRNA relative 
levels of HDAC3 in GFP+/Lin- cells knocked down for Hdac3. Values are normalized against GAPDH 
and referred to Luc. B) Immunoblot analysis of HDAC3 expression in GFP+/Lin- cells derived from 
mCGPR/PR mice and transduced with the indicated retroviral vector. Vinculin was used as a loading 
control. 
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To evaluate the effect of Hdac3-KD on colony-forming ability of PML-RARα expressing 
cells, 5,000 GFP+/Lin- cells from mCGPR/PR mice were seeded in a semi-solid methylcellulose. 
After 7 days the colonies were scored, harvested, pooled and the cells were used for the 
subsequent platings. As shown in Figure 14, Hdac3-KD led to a decrease in proliferative 
potential of PML-RARα expressing Lin- cells, as demonstrated by lower number of colonies 
recovered in serial replating experiments compared to the control (Luc). The colonies depleted 
for Hdac3 were more dispersed resembling mature cells, while Luc colonies were more 
compact (Fig. 14 A-B).  
 
Figure 14. Analysis of the proliferative potential of pre-leukemic Luc and Hdac3 knock-down 
cells. A) The graph indicates the number of colonies observed per 5,000 cells plated in serial replating 
assays. B) Colony morphology (Original magnification X1000) of individual colonies picked from first 
methylcellulose plates of either Luc or Hdac3-KD PML/RARα expressing Lin- cells. 
 
We next analyzed the effect of Hdac3-KD on the differentiation state of PML-RARα 
expressing Lin-cells, through Q-PCR and FACS analysis. As described previously (131, 132), 
PML-RARα expression hampers differentiation at myeloid stage (decrease in the number of 
cells expressing MAC.1/ GR.1 differentiation markers), which is accompanied with enhanced 
proliferative potential of Lin- cells. Downregulation of Hdac3 led to an increase in the mRNA 
relative levels of MAC.1 in PML-RARα expressing Lin- cells. MAC.1 or (cd11b/CD18 is a 
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surface integrin receptor, predominantly found on the surface of polymorphonuclear 
leukocytes (PMNs), macrophages and natural killer cells (Figure 15).  
 
Figure 15. Q-PCR analysis of MAC.1 mRNA relative levels in GFP+/ Lin- cells. The graph 
demonstrates the higher expression level of MAC.1 myeloid surface marker in GFP+/ Lin- cells 
depleted for Hdac3, values are normalized against GAPDH and referred to Luc.  
 
The induction of differentiation of pre-leukemic cells upon Hdac3-KD was further confirmed 
by immunophenotypic analysis, which revealed a greater percentage of MAC.1+ cells in 
Hdac3-KD population in comparison with Luc (Figure 16). 
 
Figure 16. Immunophenotypic analysis of GFP+/ Lin- cells depleted for Hdac3 and Luc. The plot 
indicates the percentage of MAC.1 positive cells in the GFP+/Lin- cells harvested from the first 
methylcellulose plating of sorted cells. 
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1.2 In vivo analysis of GFP+/Lin- cells knocked down for Hdac3: 
As mentioned above, our in vitro results showed that depletion of Hdac3 in the pre-leukemic 
myeloid cells, greatly impaired the differentiation block by PML-RARα leading to the 
activation of the differentiation program. Equally important, PML-RARα expression results in 
an enhanced proliferative ability of Lin- cells (132), and consistent with the observed 
differentiation induction upon Hdac3-KD, the proliferative potential of PML-RARα 
expressing Lin- cells was reduced. To test in vivo the effect of Hdac3 downregulation on the 
leukemogenic potential of PML-RARα expressing cells, lethally irradiated C57BL/6J mice, 12 
to 14 weeks old, were inoculated intravenously with 300,000 GFP+ transduced Lin- cells, 
mixed with 500,000 splenocytes obtained from a wild type (WT) mouse to support the short-
term reconstitution of hematopoiesis. Mice were observed periodically, to control survival and 
the appearance of clinical signs of leukemia. GFP+/Lin-/Hdac3-KD cells were unable to 
reconstitute the lethally irradiated syngenic recipient mice efficiently and we never observed 
the leukemia onset in the recipient mice in comparison with controls (Luc) (Figure 17). 
According to our results, Hdac3-KD impaired APL development in the recipient mice. 
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Figure 17. Percentage of mice engrafted with GFP+/Lin- cells. GFP+/Lin- cells derived from 
mCGPR/PR mice were transduced respectively, from left to right, with firefly luciferase (Luc), Hdac1, 
Hdac2 and Hdac3 shRNA retroviral vectors and after sorting they were inoculated into lethally 
irradiated C57BL/6J recipient mice. 
 
2. Role of HDAC3 at the full-leukemic stage: 
2.1 in vitro assays: 
Based on our data at the pre-leukemic stage of APL, it seems that Hdac3-KD is detrimental to 
pre-leukemic cells and it impairs APL development. Toinvestigate the role of HDAC3 at the 
leukemic stage of APL, we knocked down Hdac3 (or firefly luciferase as the control: Luc) in 
frankly leukemic APL cells. Depletion of Hdac3 on APL cells was confirmed at mRNA and 
protein levels (Fig. 18A-B). 
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Figure 18. Hdac3 depletion in APL cells. A) Analysis of HDAC3 mRNA relative levels in APL cells 
derived from 129SvEv mice, transduced with the indicated retroviral vectors. Values are normalized 
against GAPDH and referred to Luc. B) Immunoblot analysis of HDAC3 expression in GFP+/APL 
cells. Vinculin was used as a loading control. 
 
To investigate the effect of Hdac3 depletion on the proliferative potential of APL cells, 10,000 
FACS sorted GFP+/APL cells were cultured on methylcellulose. After 7 to 10 days the 
colonies were scored, pooled, harvested and the cells were used for replating, 
immunophenotyping and morphologic analysis. Colony forming unit (C.F.U) assay showed 
reduction of proliferative potential of Hdac3-KD APL cells in serial replating (Figure 19). 
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Figure 19. Analysis of the proliferative potential of Luc and Hdac3-KD APL cells in a serial 
replating assay. 10,000 GFP+/APL cells were plated in methylcellulose medium and were scored for 
colony-forming ability 10 days after plating. Error bars demonstrate standard deviation (SD) of 
biological replicates (n=3). 
 
To assess the effect of Hdac3-KD on differentiation of APL cells, cytospins were prepared 
from cells harvested from the first methylcellulose (10 days after plating) and subsequently 
they stained with May-Grünwald-Giemsa method. Interestingly, morphologic analysis of APL 
cells demonstrated that Hdac3 depletion induces a more mature cell phenotype (Fig. 20A-B). 
Mature and immature populations were defined based on their morphology, by scoring the 
percentage of mature and immature cells in each condition. In particular, the prevalence of 
mature and immature cells was analyzed morphologically in cytological slides in each case 
and the absolute percentage of mature and immature cells was reported. At least 300 cells 
were scanned for each case. 
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Figure 20. Morphological analysis of APL cells. Luc and Hdac3-KD APL cells cultured in 
methylcellulose medium were harvested after 10 days, A) representative cytospins. (Original 
magnification X1000, Olympus BX51); B) percentage of mature and immature cells. Statistical 
analysis was performed with the Fisher exact test. 
 
In summary, our results showed, Hdac3 knock-down has an antitumor activity on APL cells at 
both pre-leukemic and leukemic stages, demonstrated by reduction of clonogenicity of pre-
leukemic and leukemic cells, and enhancement of their differentiation. 
 
2.2 in vivo assays: 
Sorted GFP+/APL cells depleted for Luc and Hdac3 were transplanted into 129SvEv recipient 
mice (200,000 cells/mouse) and engraftment was followed via FACS analysis by detection of 
GFP+ cells in peripheral blood (PB). Inoculation of GFP+/shHdac3 APL cells resulted in none, 
or very few GFP+ cells in PB samples, while control GFP+ cells grew exponentially (Figure 
21). 
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Figure 21.  Percentage of GFP+ cells in the peripheral blood of mice inoculated with GFP+/APL 
cells. GFP+ was determined, through FACS analysis, 4 weeks post-transplantation on the peripheral 
blood of recipient mice (the plot shows the data for 10 mice inoculated with 200,000 GFP+/APL/ shLuc 
and 10 mice inoculated with 200,000 GFP+/APL/shHdac3 cells).  
 
Strikingly, while all Luc mice (n = 10) developed APL and were sacrificed within 50 days 
post-transplantation, as much as 7 out of 10 GFP+/shHdac3 transplanted mice remained 
disease-free for more than 300 days (Figure 22). According to this experiment it can be 
concluded that Hdac3 knock-down impairs leukemia transplantation. 
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Figure 22. Leukemia-free survival curves of 129SvEv recipient mice transplanted with APL cells. 
GFP+/APL cells constitutively depleted of Hdac3 or control shLuc were transplanted into 129SvEv 
mice and leukemia-free survival assessed by Kaplan-Meier curve. Data are represented as time since 
tumor inoculation (days). Luc vs. Hdac3: P< .0001. 
 
 
The GFP negativity in the peripheral blood of recipient mice inoculated with GFP+/shHdac3 
prompted us to further investigate the nature of developed leukemia in 3 out of 10 
GFP+/shHdac3 mice which died due to the development of APL. To determine the mRNA 
expression of HDAC3 in leukemic cells, the Q-PCR was undertaken in APL cells, collected 
from spleen of 4 control (shLuc) mice and 2 out of 3 shHdac3 mice that developed APL. APL 
cells resident at the end of the in vivo experiment showed wild-type HDAC3 expression and 
there was no down modulation at the mRNA level of Hdac3-KD leukemic mice, suggesting a 
selection against Hdac3 depletion (Figure 23). 
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Figure 23. Analysis of HDAC3 mRNA relative levels in APL cells. Q-PCR was undertaken in APL 
cellscollected from spleen of 4 control (shLuc) mice and 2/3 shHdac3 mice that developed APL to 
determine the mRNA expression of HDAC3 in leukemic cells. Individual bars represent HDAC3 
expression in leukemic cells from individual mice taken at end point. Values are normalized against 
GAPDH and referred to control (Luc). The error bars indicate SD of technical replicates. 
 
 
Since we did not detect any down modulation at HDAC3 mRNA level, we wondered if the 
leukemic cells were indeed transduced with the described vector (pRetroSuper). As showed in 
Figure 24, the qualitative PCR analysis of the APL cells derived from the spleen of leukemic 
mice were negative for the proviral integration confirming that the leukemia developed in 
shHDAC3 mice, originated from the cells not transduced with the desired vector. Thus, APL 
development, in these mice, is due to the outgrowth of GFP- cells. 
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Figure 24. PCR on genomic DNA extracted from spleen of leukemic mice. Qualitative PCR was 
undertaken on genomic DNA extracted from spleen of leukemic mice (using pRetroSuper primers). 
While the band of pRetroSuper (pRS) is present in the leukemic cells derived from control mice (Luc) 
the absence of pRS in leukemic cells from the mice inoculated with APL/GFP+/Hdac3-KD cells (the 
arrow shows the positive band), confirmed the leukemic cells are originated from cells which are not 
transduced with Hdac3 shRNA expressing retroviral construct. 
 
In addition to the above-mentioned experiments, counter selection against Hdac3 depletion 
was further confirmed by the absence of GFP+ cells in spleen of 2 shHdac3 leukemic mice, 
compared to the 4 shLuc leukemic mice (Figure 25). The third leukemia, derived from Hdac3-
KD inoculated mouse, could not be analyzed due to the advanced necrosis of the spleen. 
 
 
 
Figure 25. FACS analysis on the spleen of leukemic mice. Leukemic cells derived from spleen of 4 
leukemic shLuc and 2 leukemic shHdac3 mice were analyzed for GFP expression through the FACS 
analysis. 
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3. Using an inducible vector for depletion of Hdac3: 
Taken together, HDAC3 seems to be involved and required for the transformation mediated by 
PML-RARα, and for the maintenance of APL blasts. Since knock-down of Hdac3 was 
detrimental to pre-leukemic and APL cells, to furtherthe role of HDAC3, we set up an 
inducible Tet-On shRNAmiR30 dual color vector system, TRMPV vector. Thevectors were 
generated in collaboration with Prof. R.W Johnstone’s and Prof. J. Zuber’s lab. This inducible 
vector allows the precise tracking of both retroviral transduced cells and shRNA induction 
through two fluorescent reporters: dsRed which shows the induction of the expression of 
shRNA and Venus which shows the transduction of vector into the cells (134). In order to 
achieve our aim, APL cells were infected with the inducible vectors, the one that is called 
“double-system” described in details in the materials and methods chapter of this dissertation. 
In this system APL cells were infected with the first vector, which contained rtTA, and then 
transduced cells were selected by adding hygromycin (30μL/mL) to the cell culture for 3 days. 
Subsequently, APL cells transduced with rtTA were infected with TRMPV vector, containing 
miR30-embedded shRNA (shScrambled and shHdac3) cells transduced with the second vector 
were sorted based on the expression of Venus fluorescent protein. Unfortunately the infection 
efficiency was very low (Fig. 26A) and the APL/Venus+ sorted cells never engrafted into the 
recipient mice, although the shRNA expression was not induced by doxycycline yet. 
According to the limiting dilution experiments on APL cells the frequency of LICs has been 
estimated to be around 1 in 10,000 cells. Consequently the possibility to get transduced LICs 
with this low percentage of infection efficiency, is very low and almost infeasible. To solve 
this technical problem, we used the “all-in-one system” inducible vector described in materials 
and methods. Even this vector infected APL cells with a very low efficiency and Venus+/APL 
cells did not engraft into the recipient mice. The experiment was repeated more than once, but 
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we never observed the engraftment of APL cells into the recipients, although the HDAC3 
depletion was not induced by doxycycline. Therefore, due to the described technical reasons, 
we decided not to further pursuit this method.  
 
 
 
 
Figure 26. Percentage of APL/Venus+ cells, transduced with Tet-On inducible vector. A) 
Percentage of APL/Venus+ cells transduced with Double-System shScrambled and shHdac3. B) 
Percentage of APL/Venus+ cells transduced with All-in one system shRenilla and ShHdac3. Non-
Infected APL cells have been used as a negative control for Venus fluorescent expression.  
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4. The in vitro pharmacological inhibition of HDAC3 in pre-
leukemic cells recapitulates the observed Hdac3-KD 
phenotypes.  
Taken together, our Hdac3-knockdown results in pre-leukemia and full-blown leukemia 
support the notion that HDAC3 could play an active role in APL onset and progression and 
pinpoint HDAC3 as an attractive target for therapeutic intervention. To confirm this notion, 
translate these results to pre-clinical models of APL and to determine if Hdac3-KD 
phenotypes could be phenocopied with HDAC3 pharmacologically, we used the small-
molecule HDAC3 inhibitor, with the capacity to interfere with HDAC3 activity. We used the 
selective HDAC3 inhibitor (HDAC3i) known as RGFP966 (Repligen). 5,000 Lin- cells 
derived from mCGPR/PR mice and C57BL/6J WT mice were treated with different 
concentrations of HDAC3i (2.5 μM - 5μM and 10 μM) and plated on methylcellulose plates. 7 
days later, the number of colonies arose from the first plating of pre-leukemic cells treated 
with HDAC3i was mildly lower than the colonies formed from  the controls (Non-treated pre-
leukemic cells), while in the 2nd and 3rd replating of pre-leukemic cells treated with the same 
concentrations of RGFP966, there was a dramatic reduction in the number of colonies (Figure 
27).  
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Figure 27. Colony forming ability of PML-RARα expressing Lin- cells upon administration of 
HDAC3i. Colony forming unit assay was done on PML-RARα expressing Lin- cells treated with 3 
different concentrations of RGP966.  After 7 days the colonies were scored, pooled and cells were 
harvested and used for subsequent platings. The error bars represent standard deviation of the technical 
replicates. NT stands for non-treated PML-RARα expressing Lin- cells. 
 
In addition, the selectivity of HDAC3 inhibitor for tumorigenic cells against normal ones was 
observed by the mild effect of RGFP966 on the colony-forming ability of Lin- cells derived 
from WT mice in comparison with Lin- cells derived from PML-RARα expressing cells and 
APL cells (Figure 28). 
 
Figure 28. Comparative proliferative potential of wild type, PML-RARα expressing Lin- and 
APL cells. While the colony forming ability of WT Lin- cells were reduced mildly after the treatment 
with HDAC3i, the clonogenicity of PML-RARα expressing Lin- and APL were reduced dramatically. 
89 
 
Furthermore, treatment of PML-RARα expressing Lin- cells with HDAC3 selective inhibitor 
(RGFP966) caused induction of differentiation of pre-leukemic myeloid cells. After scoring 
the colonies from the 1st methylcellulose, the cells were harvested and used for serial replating 
and in parallel for morphologic analysis through the May-Grünwald-Giemsa method (Figure 
29). 
 
Figure 29.  Morphologic analysis of PML-RARα expressing Lin- cells, after treatment with 
RGF966. A) Representative cytospins related to the cells harvested after plating in the 1st 
methylcellulose medium. (Original magnification X1000, May-Grünwald-giemsa staining, Olympus 
BX51). B) Percentage of mature and immature cells. Statistical analysis was performed with the Fisher 
exact test. 
 
These results demonstrate that pharmacologic inhibition of HDAC3 enzymatic activity in pre-
leukemic cells mimics the Hdac3 knock-down phenotype. 
5. Pharmacological inhibition of HDAC3 enzymatic activity in 
APL cells mimics the phenotype of Hdac3-KD. 
Based on our data in APL cells, we showed that Hdac3-KD results in reduction of 
clonogenecity of APL cells and increases their differentiation. Thus, we tested the effect of 
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RGFP966, the HDAC3 selective inhibitor on frankly leukemic APL cells. To achieve our goal, 
10,000 APL cells were treated with different concentrations of RGFP966 (0.05 μM, 0.1 μM, 
0.5 μM and 1 μM), and seeded on methylcellulose medium. 10 days after plating, the colonies 
were scored, harvested, pooled and used for further analysis by cytospins and serial replating 
experiments. Consistent with our results on pre-leukemic cells and with Hdac3-KD effect on 
proliferative potential of APL cells, RGFP966 reduced the clonogenicity of APL cells in 
C.F.U assay (Figure 30). 
 
Figure 30. C.F.U assay on APL cells, treated with RGFP966. The APL cells were treated with 
RGFP966 at 4 different concentrations (0.05 μM, 0.1 μM, 0.5 μM and 1 μM), NT stands for non-
treated sample (DMSO was used as vehicle). 
 
Cytospins were also prepared from the harvested cells and observed microscopically for 
morphologic analysis and consistent with Hdac3-KD phenotype there was an induction of 
differentiation upon treatment of APL cells with RGFP966 (Figure 31). 
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Figure 31. Morphological analysis of APL cells treated with different concentrations of 
RGFP966. A) representative cytospins (original magnification X1000, Olympus BX51), while  Non-
treated sample shows mainly the morphology of promyelocytes,  the APL treated samples shows 
mainly the morphology of more mature cells such as; macrophages B) Plot of percentage of mature and 
immature  cells. The statistical analysis was performed with the Fisher exact test. 
 
The induction of differentiation in APL cells treated with low concentrations of RGFP966, 
was further confirmed by FACS analysis carried out on the cells harvested from the 1st 
methylcellulose (Figure 32). In this experimental condition, consistent with the phenotypes 
obtained upon Hdac3-KD in frankly leukemic cells, we observed reduction of clonogenicity of 
APL cells accompanied with an induction of myeloid differentiation of APL cells. 
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Figure 32. GR.1 and MAC.1 positive cells increase in APL cells upon the treatment with RFP966. 
An increased percentage of cells positive for GR-1(Ly-6G) or MAC-1 (CD11b) confirms that low 
concentrations of RGFP966 trigger differentiation in APL cells similar to Hdac3 depletion. 
 
5.1  HDAC3 inhibition cooperates with ATRA in reduction of 
clonogenicity of APL cells 
There are some studies on APL patients in whom a combination of ATRA and an HDACi has 
been used to assess whether there was an improvement in response to these compounds and 
consequently a complete remission. In one of those studies a combination of  HDACi 
phenylbutyrate and ATRA led to induced histone hyperacetylation and complete remission in 
a case of highly resistant promyelocytic leukemia even though the disease was relapsed after 7 
months (135). We thus asked whether there is a cooperative activity between RGFP966 and 
ATRA. We treated 10,000 frankly leukemic APL cells either with RGFP966 as single agent, 
or with ATRA, and with both compounds at the concentrations indicated in the Figure 33. 
Then the cells were seeded on methylcellulose medium. After 10 days, the colonies were 
scored. As it can be seen in C.F.U assay, there is a synergistic effect between ATRA and 
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RGFP966 in reducing the clonogenicity of APL cells. This suggests that these two compounds 
can be used as a potential combination therapy for the treatment of APL. 
 
Figure 33. Synergistic effect of ATRA and RGFP966 on reducing the colony forming ability of 
APL cells. RGFP966 (HDAC3 inhibitor) was used at 4 different concentrations; 1μM, 0.5μM, 0.1μM 
and 0.05μM. ATRA has been used at 3 different concentrations; 1μM (High), 0.1μM (intermediate) 
and 0.01μM (Low). The cooperative activity of two compounds in reducing the colony forming ability 
of the cells can be seen at all concentrations in combination therapy. 
 
This project has been done in collaboration with two other groups: Prof. R.W Johnstone’s lab 
from The Sir Peter MacCallum Department of Oncology and Prof. J. Zuber’s lab from 
University of Melbourne and Institute of Molecular Pathology, Vienna, Austria. The data 
obtained in APL model have been generated by our group and further the role of HDAC3 in 
Eμ-myc lymphoma cells has been investigated by the lab of R.W. Johnstone and its role also 
been assessed in AML model driven by MLL-AF9 cells by the lab of J. Zuber. Thus, here the 
data generated on the role of HDAC3 in two other models, are summarized.  
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6. Investigating the role of HDAC3 in AML driven by MLL-
AF9:NrasG12D 
In a published pooled shRNA screen from Zuber’s lab the potential sensitivities of aggressive 
MLL-AF9;NrasG12D AML to HDAC inhibition, had been observed (136). In particular, they 
have evaluated this phenotype by depleting Hdacs1-11 using independently derived shRNAs 
and utilized competitive assays to monitor their effects on representation of AML cells in 
vitro. Strikingly, in contrast to any other single HDAC, cells depleted of Hdac3 exhibited 
reduced representation over 12 days of serial passaging (49 shRNAs in total, 3 to 5 shRNAs 
per each individual HDAC have been used) (Figure 34). 
 
Figure 34. AML cells (MLL-AF9/NrasG12D) have a unique sensitivity to Hdac3 depletion. RNAi 
mediated screen of all 11 classical HDAC isoforms in AML cells driven by MLL-AF9/NrasG12D 
demonstrates dependency on HDAC3 expression. The bar chart demonstrates the fold change in GFP 
expression as a ratio between day 2 post-infection and day 12. Between 3 to 5 shRNAs have been used 
for each HDAC isoform. 
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6.1  In vivo assays: 
     The in vitro study reproducibly demonstrates that Hdac3 depletion reduces the proliferation of 
AML cells. Prof. Zuber’s Lab sought to confirm this result in vivo by using the Tet-On 
inducible vectors. Luciferase –expressing MLL-AF9;NrasG12D AML cells transduced with 
dox-inducible shHdac3 (n=14) or non-targeting shRenilla (n=12) constructs (pTRMPV-Neo) 
were transplanted into CD45.1+ mice and shRNA expression was induced two days after tumor 
inoculation by addition of doxycycline to food and drinking water, (shRNA expression can be 
followed by dsRed expression). Remarkably, in vivo depletion of Hdac3 significantly reduced 
tumor burden (Figure 35A) and although shHdac3 mice finally died due to the development 
of leukemia, but showed survival benefit in comparison with shRen inoculated mice (Figure 
35B). 
 
Figure 35. Hdac3 depletion reduces tumor burden and/or significantly extends the survival of 
mice bearing AML. A) Tumor burden was assessed by bioluminescent imaging following 8 days of 
doxycycline treatment. B) Kaplan-Meier curve for survival analysis of mice bearing transplanted AML 
tumor with indicated pTRMPV-Neo constructs. Day 0 indicates the day of doxycycline treatment. 
  
At terminal disease stage, bone marrow of control mice predominantly showed shRen-
expressing cells (dsRed+/Venus+), while recipients of shHdac3-expressing cells showed an 
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outgrowth of AML cells that had evaded shRNA expression (CD45.2+/dsRed-/Venus+) (Fig. 36 
C-D), indicating a strong selection against effective Hdac3 suppression. 
 
Figure 36. Strong selection against Hdac3 depletion, results in AML development in the recipient 
mice. A) FACS analysis of Venus+/dsRed+ cells at terminal disease stage; (while control mice 
inoculated with shRen are Venus+/dsRed+, shHdac3 recipient mice are Venus+/dsRed-). B) Quantitation 
of the percentage of Venus/dsRed expressing tumor cells remaining at terminal disease stage.  
 
 
7. HDAC3 has a crucial role in the survival of lymphoma cells       
driven by Eμ-myc: 
7.1  In vitro assays: 
Prof. Ricky’s lab focused on HDACs inhibited by currently approved HDACi (HDAC1, 2, 3, 
and 6) in Eµ-Myc lymphoma. shRNAs were validated in NIH-3T3 cells using pLMS 
constitutive retroviral vector by western blot (Figure 37). At least 2 shRNAs effectively 
depleted each individual HDAC were selected and utilized in subsequent experiments.  
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Figure 37.  Validation of shRNAs against Hdac1, Hdac2, Hdac3 and Hdac6 in NIH3T3 cells. NIH-
3T3 cells were transduced with retroviral pLMS vectors containing various shRNAs against: A) 
Hdac1; B) Hdac2; C) Hdac3; and D) Hdac6 (3-4 per HDAC isoform), FACS sorted GFP+ cells, 
expanded in culture and then assessed for on-target Hdac depletion by western blot. The depletion of 
Hdac6 was also confirmed by probing for hyperacetylated tubulin. Individual shRNAs (n=2) that 
demonstrated effective knockdown for each HDAC isoform were chosen for subsequent experiments 
in Eµ-Myc lymphoma cells. 
Eμ-myc tumor cells were transduced with constitutive (pLMS) or dox-inducible (pTRMPV-
Neo) retroviral vectors. FACS sorted to approximately 50% GFP or Venus positive cells and  
mixed with 50% of non-transduced cells. Then they were serially passaged (± dox) for up to  
13 days (for constitutive system) or 15 days (for inducible system). The percentage of GFP 
(pLMS) or Venus/dsRed double positive (pTRMPV-Neo) cells were assessed every second 
day (days 1-13 or 1-15) and data were normalized to day 0 or day 1. The exquisite sensitivity 
of Eµ-Myc lymphoma cells to constitutive depletion of Hdac3 is depicted in Fig. 38A. 
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Moreover, Eµ-myc cells transduced with dox-inducible pTRMPV-Neo retroviral vectors, 
indicated that depletion of Hdac3 reproducibly led to the loss of representation of Eµ-Myc 
lymphoma. Importantly, suppression of no other individual HDAC isoform reproducibly 
altered the growth/survival of Eµ-Myc lymphoma (Fig. 38B). Knock-down of individual 
Hdacs in Eµ-Myc tumors were validated using Q-PCR and western blot analysis.  
 
Figure 38. Eμ-myc lymphoma cells show sensitivity to Hdac3-KD. Competitive proliferation assay 
has been utilized to investigate the proliferative effects of depleting Hdac1, 2, 3 and 6 in Eµ-Myc 
lymphoma cells. A) Following constitutive depletion of Hdacs1, 2, 3 or 6 in Eµ-Myc lymphoma cells, 
the complete loss of representation of cells expressing shHdac3 is demonstrated, while acute effects are 
observed in cells depleted of Hdac1. B) Schematic representation of the dox-inducible vector system 
(pTRMPV-Neo) utilized to inducibly deplete HDAC isoforms and bar charts demonstrating the 
expression of Venus+/dsRed+ cells following serial passaging in dox-containing culture media. C) Q-
PCR demonstrates depletion of individual HDAC isoform expression. D) Western blots demonstrating 
the efficiency of inducible Hdac depletion following doxycycline treatment (3 days) of Eµ-Myc tumor 
cells. Hyper-acetylated tubulin (Ac tubulin) was employed as surrogate readout for Hdac6 depletion. 
Note the variability of background levels of hyper-acetylated tubulin (for example shHdac1). β-actin 
was used as a loading control. 
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7.2  In vivo assays: 
Next, researchers from Prof. Ricky’s lab transplanted Eµ-Myc lymphoma transduced with 
FACS sorted Venus+/dox-inducible shScrambled, shHdac3.1659 or shHdac3.201 into CD45.1+ 
mice (n=36). On day 3 post-inoculation, mice were fed doxycycyline in food and water to 
initiate expression of shRNAs in vivo. On day 10, mice were bled and then sacrificed. In vivo 
depletion of Hdac3 significantly reduced white-blood cell count, percentages of Venus+ tumor 
cells in PB and spleen weight. As per AML studies, outgrowth of non-transduced Eµ-Myc 
cells (Venus-) (Figure 39) in mice at ethical endpoints prevented any survival advantage (data 
not shown). 
 
Figure 39. Outgrowth of Venus- cells, led to lymphomagenesis in the recipient mice. 
Representative histograms of donor-derived (CD45.2+) Eµ-Myc lymphoma cells (day 10) demonstrating 
the outgrowth of non-transduced (Venus negative cells). 
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While all three leukemias/lymphomas demonstrated significant anti-proliferative effects 
following Hdac3 depletion in vitro and in vivo, Hdac3 depletion in APL cells also triggered 
differentiation and led to a more mature phenotype, suggesting that HDAC3 can represent a 
good molecular target for developing new drugs. Furthermore, RGFP966 in APL cells was 
able to mimic Hdac3 depletion by reducing clonogenicity and upregulating the myeloid 
differentiation markers Gr.1 and Cd11b (MAC.1) concomitant with morphological changes 
reminiscent of differentiated myeloid cells. This suggests that low dose HDAC3-selective 
inhibition in patients with APL may promote tumor cell differentiation and enable tumor 
remissions without the need for toxic chemotherapy. 
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Discussion 
Epigenetic abnormalities observed in cancer can be targeted pharmacologically. As an 
example of epigenetic therapy HDACi, that target multiple HDACs, are effective for the 
treatment of CTCL. Epigenetic drugs, however, have single agent efficacy only in selected 
hematological malignancies, underlying the need for a better understanding of epigenetic 
alterations and of epigenetic enzymes in cancer. Therefore, my PhD project has been based on 
the hypothesis that epigenetic therapies have to be directed against specific functional 
epigenetic alterations present in cancer cells to achieve maximal effects. 
Currently due to this fact that most of available HDACi are pan-HDACi and behave in a non-
selective manner, the clinical utility of these agents is limited. Thus, to better use HDACi we 
need to understand the role of individual HDACs in tumorigenesis. In the last two decades 
there has been a considerable effort in understanding the biological roles and functions of 
HDACs. Conclusively, identification of the HDAC isoforms most critical for tumor promotion 
could lead to the design of more targeted therapies and reduced toxicities. 
Based on these premises, my project has been planned to study the role of HDAC3 in the 
development of APL, and in maintenance of the disease. As mentioned previously, the study 
has been done in collaboration with two other groups: Prof. R.W Johnstone’s Lab (from The 
Sir Peter MacCallum Department of Oncology, University of Melbourne), which provided 
data generated on Eμ-myc lymphoma model and Prof. J. Zuber’s lab (from Institute of 
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Molecular Pathology, Vienna, Austria), which provided data generated on the MLL-
AF9/NrasG12D model.  
The rational for assessing the role of HDAC3 in these 3 specific hematological malignancies 
(APL, AML driven by MLL-AF9 and Eμ-myc lymphoma) is as mentioned before; APL is the 
first model disease in which the involvement of HDACs has been demonstrated. Thus, our 
group is studying the role of individual HDACs in the pathogenesis of APL caused by the 
fusion protein PML-RARα. The group has previously shown that HDAC1 and to a lesser 
extent HDAC2 has a dual role in APL: oncosuppressor in establishment (pre-leukemic stage), 
oncogene in maintenance (leukemic stage) of the disease, and that HDACi can have different 
effects on bulk vs. leukemic stem cells (87). From the previous work of my group, this general 
statement can be further refined as follows: different HDACs may play distinct roles at 
different stages of tumor development, and within the tumor mass they play different roles in 
distinct cell compartments (bulk vs. cancer stem cells). Taken together, through a better 
understanding of the role of HDACs in leukemia, we can identify better treatments with 
epigenetic drugs.  
In this study, the effects of Hdac3 depletion has been assessed also in murine MLL-AF9 
NrasG12D driven AML. MLL is one of the mammalian homologs of the Drosophila trithorax 
genes, and is highly expressed in progenitor cells and downregulated during cellular 
differentiation and maturation. Chromosomal translocations leading to the formation of MLL 
fusion proteins are involved in 5–10% of AML. MLL interacts with HATs, and possesses 
histone methyltransferase activity towards Lys4 of histone H3 through its Su(var)3-9enhancer 
of zeste trithorax domain; it is therefore considered to be a positive regulator of gene 
expression. MLL rearrangements are subdivided into reciprocal chromosomal translocations, 
deletions, and inversions. Among the major fusion partners of MLL are the transcriptional 
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activators AF4, AF9, AF10, and ENL. These fusion proteins usually lead to the 
overexpression of MLL target genes, including HOXA9 and MEIS1, which are required for 
HSC self-renewal. The leukemogenic transformation mediated by MLL fusion proteins is 
abolished in vivo by point mutations in its CXXC motif (the DNA-binding motif), which is 
retained in all MLL fusion proteins. This motif interacts with corepressor proteins such as 
HDAC1 and the polycomb group protein BMI-1. MLL fusion partners activate the 
transcriptional elongation of MLL target genes through epigenetic mechanisms. Whereas 
MLL loses its own transcriptional activation capacity through the translocation process, the 
fusion proteins form the superelongation complex via interactions with positive transcription 
elongation factor b, cyclin-dependent kinase 9, and cyclin T1. The superelongation complex 
phosphorylates RNA polymerase II. Then, DOT1L is recruited to the MLL fusion complex by 
interaction with ENL, AF9, and AF10. DOT1L, the only known histone H3 Lys79 
methyltransferase, has been shown to have a broad role in transformation mediated by MLL 
fusion proteins through interactions with multiple MLL fusion partners, and its gene 
disruption in mice has pointed to a pivotal role of DOT1L in hematopoiesis, cardiac function, 
and the development of leukemia. Mistargeting of DOT1L to HOX9A and MEIS1 through its 
interaction with MLL fusion partners leads to the constitutive transcriptional activation of 
these genes through aberrant hypermethylation of histone H3 Lys79, which in turns results in 
leukemic transformation (17).  
The complexity of chromatin-remodeling enzymes recruited by MLL fusion proteins has been 
supported by the involvement of additional epigenetic mechanisms in its molecular 
pathogenesis: MLL-AF9 interacts with TIP60 histone acetyltransferase, histone deacetylases 
and polycomb group proteins. An initial hint for the involvement of HDACs in the 
pathogenesis of MLL-rearranged leukemia stems from the study conducted by Xia et al, which 
showed the binding of class I HDACs to the repression domain of MLL protein that results in 
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silencing of the respective genes (137). Based on our study, it seems that HDAC3 is one of the 
critical HDACs involved in the leukemogenic potential of MLL-AF9 and it can be considered 
as an epitarget for the treatment of MLL-rearranged leukemias. 
 
The effects of Hdac3 depletion in Eμ-myc lymphoma have been demonstrated by this study. 
Indeed overexpression of the proto-oncogene MYC is one of the most frequent genetic 
alterations found in human cancers. In Eμ-myc mice, the intronic enhancer of the μ-
immunoglobulin heavy chain drives the expression of Myc (138). Recently a study conducted 
by Dovey et al. demonstrated that deletion of Hdac1 and Hdac2 in T cells caused neoplastic 
transformation of immature T cells concomitant with elevated levels of MYC and decreased 
tumour suppressor p53 activity (139). Then consistent with a putative genetic interaction 
between MYC and HDAC1 or HDAC2, Prof. Johnstone’s lab showed that knockdown of 
these Hdacs in hematopoietic progenitor cells accelerated MYC-driven lymphomagenesis 
(87). Respecting the results of the current study, one of the possible mechanisms of HDAC3 
involvement in the pathogenesis of Eμ-myc lymphoma is the association of HDAC3 activity 
with MYC oncogene. Possibly, HDAC3 cooperates with MYC in p53 dysfunctionality and 
therefore the tumorigenic cells escape from apoptosis. 
 
Experimentally, we have decided to use a selective knock-down of Hdac3 in primary murine 
hematopoietic progenitors to study the biological effects of the KD in vitro and in vivo and to 
better understand the response of tumor cells to novel treatments with epigenetic drugs. 
In this study we have shown that HDAC3 has a cooperative activity with PML-RARα fusion 
protein in full leukemic transformation. Knock-down of Hdac3 resulted in loss of proliferative 
potential and induction of myeloid differentiation of pre-leukemic and frankly leukemic APL 
cells. A possible mechanism for the induction of differentiation in APL cells upon Hdac3-KD 
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can be inferred from a previous study from Villa et al, (140). Indeed, HDAC3 appeared to 
have an important role in the PML-RARα associated repressor complex. Actually MBD1, a 
conserved protein that binds to methylated DNA, cooperates with PML-RARα in repressing 
the transcription of target genes and HDAC3 mediates this cooperation. In this study Hdac3-
KD in NB4 leukemic cells led to a release of RARβ2 repression (the canonical target of PML-
RARα). This could happen also for the differentiation genes, which are repressed upon PML-
RARα expression. Thus, when Hdac3 is downregulated, it could lead to loss of transcriptional 
repression of differentiation promoting genes. Moreover, in another study from Martens et al, 
(141) it has been showed that PML-RARα/RXR functions as a local chromatin modulator and 
that specific recruitment of HDAC activities to genes important for hematopoietic 
differentiation (such as SPI1, GFI1 and RUNX1), RAR signaling and epigenetic control, is 
essential to its transforming potential.  
Additionally, we uncovered that depletion of Hdac3 in PML-RARα expressing pre-leukemic 
and leukemic cells caused the impairment of APL development upon transplantation into 
recipient mice, supporting the notion that HDAC3 has an oncogenic activity in tumor initiation 
and maintenance. Additionally and potentially linked to these results, Prof. Zuber’s lab has 
observed the sensitivity of AML cells (driven by MLL-AF9/Nras G12D) to depletion of Hdac3 
and beneficial enhanced survival of mice inoculated with Hdac3 depleted cells compared to 
the controls. Furthermore, anti-proliferative effect of Hdac3 knock-down on Eμ-myc 
lymphomas has been shown by Prof. Johnstone’s Lab. However, in contrast to a recent report 
that Hdac3 suppression induces apoptosis in multiple myeloma cells (142) researchers from 
Prof. Johnstone’s were unable to detect any significant level of apoptosis following Hdac3 
depletion in Eμ-Myc lymphoma. Indeed, loss of Hdac3 in Eμ-Myc tumor cells led to an anti-
proliferative response that was not attenuated by over-expression of prosurvival BCL-2, or 
pharmacological inhibition of pro-apoptotic caspases. 
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Moreover, anti-proliferative effects of HDACi point to a role for HDACs in tumorigenesis. In 
this regard, HDACs have been widely considered to have oncogenic roles, especially given the 
impressive anti-proliferative and apoptotic responses mediated by HDACi in certain 
hematological malignancies (88). Strikingly, we have demonstrated that depletion of Hdac3, 
through a functional knock-down approach consistently attenuated tumor cell differentiation in 
APL.  
Furthermore, we took advantage of a HDAC3 selective inhibitor RGFP966, to assess whether 
pharmacological inhibition of HDAC3 activity can reproduce the same phenotypes obtained 
upon genetic depletion of Hdac3 and sequentially the drug can be used in pre-clinical models 
of cancer. In agreement with knock-down experiments, treatment of pre-leukemic cells with 
HDAC3-selective inhibitor RGFP966 reproduced the same biological effects as Hdac3-KD, 
and treatment of APL cells with RGFP966 induced differentiation at low micro molar 
concentrations. This suggests that low dose HDAC3-selective inhibition in patients with APL 
may promote tumor cell differentiation and enable tumor remissions without the need for toxic 
chemotherapy, similar to that observed with ATRA or arsenic trioxide (143).  
Interestingly, treatment of wild-type cells and pre-leukemic and full-leukemic cells with 
RGFP966 showed the higher sensitivity of PML-RARα expressing cells compared to the WT 
cells, which is in agreement with the notion that HDACi are more effective on transformed 
cells rather than normal cells. Notably, this study suggests that HDAC3 could be a good target 
for the treatment of hematological malignancies, such as APL and lymphoma.  
Besides our study, there are other studies, which showed the oncogenic role of HDAC3 in a 
subset of cancer, such as colon cancer. In colon cancer Hdac3-KD led to reduction of β-
catenin levels, which downregulated c-myc and eventually caused the reduced cancer cell 
proliferation (144). 
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It has been shown that HDAC3 is also required for maintenance of chromatin structure and 
genome stability through the maintenance of an efficient DNA repair. Indeed, HDAC3 activity 
is required for an appropriate Non-homologous end joining (NHEJ) and homologous-
recombination (HR), the repair mechanisms involved in double-strand breaks. These HDAC3 
functions may impact on its usefulness as a therapeutic target in cancer and other diseases 
(36).  
There are some HDACi, such as SAHA, that are well tolerated in vivo. SAHA may cause S-
phase associated DNA damage for cycling cancer cells during the therapeutic window (3-6 
hours) in which SAHA is active, whereas it has mild impact on non-cycling normal cells. 
Actually, in normal proliferating cells SAHA-mediated DNA damage is repaired by the proper 
activity of DNA damage response. On the other hand, one of the drawbacks in using these 
agents is that when they are used at too high-doses or for too long time, they cause genomic 
instability in normal cells and consequently secondary cancers arise as side effects. Similar to 
almost all cancer therapeutics, HDAC3 inhibitors can develop a therapeutic window and, 
although continuous inhibition of HDAC3 is detrimental, transient inhibition by HDAC3 
selective inhibitor that can be frequently repeated could be safe. 
In summary, this is the first study to provide genetic and pharmacological information 
regarding sensitivities of three distinct hematological tumor types to suppression of Hdac3 in 
vitro and in vivo. Using advanced genetic techniques and pharmacological inhibitors we 
demonstrate that depletion of Hdac3 reduces the proliferation and/or triggers the 
differentiation of tumor cells.  
Taken together, our novel genetic and pharmacological approach suggests that HDAC3-
selective inhibitors may be effective for the treatment of hematological malignancies and that 
newly developed agent should prioritize HDAC3 as the molecular target to induce effective 
108 
 
anti-tumor responses. However, complete understanding of the mechanisms mediated by 
HDAC3 in tumor cells vs. normal cells, has obvious therapeutic importance. Whether the 
inhibition of HDACs additional to those examined to date in leukemia, including the class I 
HDAC8 and the class II HDACs 4, 5, 6, 7, 9 and 10, are also required for the HDACi response 
remains to be determined. 
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